Stabilizing agents as buffering systems for lyophilized PCR reagents
Patent Information
- Application Number
- PCT/US2026/017202
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-12-03
- Filing Date
- 2026-02-27
- Publication Date
- 2026-11-19
AI Technical Summary
Developing a suitable buffering system for lyophilized DNA amplification reagents that is compatible with the lyophilization process and does not detrimentally affect the stability of polymerase enzymes and small molecules is challenging.
Incorporating arginine into the pH buffer system of lyophilized reagents to stabilize the amplification mixture across a predetermined pH range, enhancing the stability and efficiency of the amplification process.
The use of arginine in the pH buffer system maintains consistent PCR performance and increases the thermal stability of enzymes and nucleotides, ensuring reliable amplification results.
Smart Images

Figure US2026017202_19112026_PF_FP_ABST
Abstract
Description
STABILIZING AGENTS AS BUFFERING SYSTEMS FOR LYOPHILIZED PCR REAGENTSTECHNICAL FIELD
[0001] This disclosure relates generally to formulation of reagents for nucleic acid processing of biological samples. More specifically, this disclosure relates to pH buffering for lyophilized reagents.BACKGROUND
[0002] DNA amplification reagents are often distributed in lyophilized form for better stability and to remove the need for cold chain storage. Design and development of these reagents are complicated by the presence of critical components with different chemical natures, such as polymerase enzyme(s) and an array of small molecules, in particular deoxy -nucleotides. One difficulty involves identifying a suitable buffering system that is compatible with the lyophilization process and is not detrimental to the stability of the enzy me nor to the stability of the small molecules. Often times, developers solve this problem by coupling a buffer system with a combination of molecules (stabilizers) that protect the integrity of the critical components, thus increasing the complexity of the formulation.SUMMARY
[0003] In a first implementation, a composition for processing a biological sample includes lyophilized material. The lyophilized material includes an amplification mixture for amplifying one of nucleic acids or deoxynucleotide triphosphates (dNTPs) and a pH buffer system including arginine in an amount sufficient to increase stability of the amplification mixture across a predetermined pH range.
[0004] Any single one or any combination of the following features may be used with the first implementation.
[0005] In various forms of the first implementation, the amount of the arginine is between 20 and 180 mM.
[0006] In various forms of the first implementation, the amount of the arginine is between 40 and 80 mM.
[0007] In various forms of the first implementation, the predetermined range is up to and includes 0.9 pH units.
[0008] In various forms of the first implementation, at least a portion of the predetermined range falls within pH 8.59 to pH 9.59.
[0009] In various forms of the first implementation, the portion of the predetermined range falls within pH 8.59 to pH 9.2.
[0010] In various forms of the first implementation, the arginine further thermally stabilizes one or more enzymes within the amplification mixture.
[0011] In various forms of the first implementation, the arginine promotes amplification efficiency and accuracy of the amplification mixture.
[0012] In various forms of the first implementation, the arginine further increases glass transition temperature of the lyophilized material.
[0013] In various forms of the first implementation, the arginine further increases stabi 1 i ty of one or more nucleotides in the amplification mixture.
[0014] In various forms of the first implementation, the amplification mixture includes an elongation polymerase.
[0015] In various forms of the first implementation, the elongation polymerase is thermostable and retains resistance to thermal denaturation in the presence of arginine.
[0016] In various forms of the first implementation, the amplification mixture includes an elongation polymerase, and the composition includes 100 to 200 mM salt, 0 to 6 M of a polymerase chain reaction (PCR) coadjutant, and 0 to 0.2 %V detergent.
[0017] In various forms of the first implementation, the composition comprises 20 to 40 mM of the salt.
[0018] In various forms of the first implementation, the composition comprises 0.045 to 0.228 M of the PCR coadjutant.
[0019] In various forms of the first implementation, the composition comprises 0.112 to 0.19 mM of the PCR coadjutant.
[0020] In various forms of the first implementation, the composition comprises 0 to 0.2 %V of the detergent.
[0021] In various forms of the first implementation, the composition maintains consistent polymerase chain reaction (PCR) performance for a cycle threshold (Ct) value of approximately 13 across 0.9 pH units.
[0022] In various forms of the first implementation, the composition further comprises 1 to 40 mM of magnesium salt.
[0023] In various forms of the first implementation, the composition comprises 5 to 8 mM of the magnesium salt.
[0024] In various forms of the first implementation, the lyophilized material includes lyophilized particles.
[0025] In a second implementation, a method of formulating a consumable for processing a biological sample includes selecting a buffer system including a selected amount of arginine. The method also includes adding the buffer system to an amplification mixture for amplifying one of nucleic acids or deoxynucleotide triphosphates (dNTPs), where the selected amount of arginine is sufficient to increase stability- of the amplification mixture across a predetermined pH range. The method further includes lyophilizing a composition including the amplification mixture and the buffer system to form a lyophilized material.
[0026] Any single one or any combination of the following features may be used with the second implementation.
[0027] In various forms of the second implementation, the amount of the arginine is between 40 and 180 mM.
[0028] In various forms of the second implementation, the amount of the arginine is between 20 and 80 mM.
[0029] In various forms of the second implementation, the predetermined range is up to and includes 0.9 pH units.
[0030] In various forms of the second implementation, at least a portion of the predetermined range falls within pH 8.59 to pH 9.59.
[0031] In various forms of the second implementation, the portion of the predetermined range falls within pH 8.59 to pH 9.2.
[0032] In various forms of the second implementation, the arginine further thermally stabilizes one or more enzymes within the amplification mixture.
[0033] In various forms of the second implementation, the arginine promotes amplification efficiency and accuracy of the amplification mixture.
[0034] In various forms of the second implementation, the arginine further increases glass transition temperature of the lyophilized material.
[0035] In various forms of the second implementation, the arginine further increases stability of one or more nucleotides in the amplification mixture.
[0036] In various forms of the second implementation, the amplification mixture includes an elongation polymerase.
[0037] In various forms of the second implementation, the elongation polymerase is thermostable and retains resistance to thermal denaturation in the presence of arginine.
[0038] In various forms of the second implementation, the amplification mixture includes an elongation polymerase, and the composition includes 100 to 200 mM salt, 0.045 to 0.19 mM of a polymerase chain reaction (PCR) coadjutant, and 0 to 0.2 %V detergent.
[0039] In various forms of the second implementation, the composition comprises 20 to 40 mM of the salt.
[0040] In various forms of the second implementation, the composition comprises 0.045 to 0.228 mM of the PCR coadjutant.
[0041] In various forms of the second implementation, the composition comprises 0.112 to 0.19 mM of the PCR coadjutant.
[0042] In various forms of the second implementation, the composition comprises 0 to 0.2 %V of the detergent.
[0043] In various forms of the second implementation, the composition maintains consistent polymerase chain reaction (PCR) performance for a cycle threshold (Ct) value of approximately 13 across 0.9 pH units.
[0044] In various forms of the second implementation, the composition further comprises 1 to 40 mM of magnesium salt.
[0045] In various forms of the second implementation, the composition comprises 5 to 8 mM of the magnesium salt.
[0046] In various forms of the second implementation, the lyophilized material includes lyophilized particles.
[0047] In a third implementation, a method comprising lyophilizing a composition including an amplification mixture for amplifying one of nucleic acids or deoxynucleotide triphosphates (dNTPs), and a buffer system to form a lyophilized material, wherein the buffer system comprises an amount of arginine sufficient to increase stability of the amplification mixture across a predetermined pH range.
[0048] Any single one or any combination of the following features may be used with the third implementation.
[0049] In various forms of the third implementation, the amount of the arginine is between 40 and 180 mM.
[0050] In various forms of the third implementation, the amount of the arginine is between 20 and 80 mM.
[0051] In various forms of the third implementation, the predetermined range is up to and includes 0.9 pH units.
[0052] In various forms of the third implementation, at least a portion of the predetermined range falls within pH 8.59 to pH 9.59.
[0053] In various forms of the third implementation, the portion of the predetermined range falls within pH 8.59 to pH 9.2.
[0054] In various forms of the third implementation, the arginine further thermally stabilizes one or more enzymes within the amplification mixture.
[0055] In various forms of the third implementation, the arginine promotes amplification efficiency and accuracy of the amplification mixture.
[0056] In various forms of the third implementation, the arginine further increases glass transition temperature of the lyophilized material.
[0057] In various forms of the third implementation, the arginine further increases stability7of one or more nucleotides in the amplification mixture.
[0058] In various forms of the third implementation, the amplification mixture includes an elongation polymerase.
[0059] In various forms of the third implementation, the elongation polymerase is thermostable and retains resistance to thermal denaturation in the presence of arginine.
[0060] In various forms of the third implementation, the amplification mixture includes an elongation polymerase, and the composition includes 100 to 200 mM salt, 0.045 to 0.19 mM of a polymerase chain reaction (PCR) coadjutant, and 0 to 0.2 %V detergent.
[0061] In various forms of the third implementation, the composition comprises 20 to 40 mM of the salt.
[0062] In various forms of the third implementation, the composition comprises 0.045 to 0.228 mM of the PCR coadjutant.
[0063] In various forms of the third implementation, the composition comprises 0.112 to 0.19 mM of the PCR coadjutant.
[0064] In various forms of the third implementation, the composition comprises 0 to 0.2 %V of the detergent.
[0065] In various forms of the third implementation, the composition maintains consistent polymerase chain reaction (PCR) performance for a cycle threshold (Ct) value of approximately 13 across 0.9 pH units.
[0066] In various forms of the third implementation, the composition further comprises 1 to 40 mM of magnesium salt.
[0067] In various forms of the third implementation, the composition comprises 5 to 8 mM of the magnesium salt.
[0068] In various forms of the third implementation, the lyophilized material includes lyophilized particles.
[0069] In a fourth implementation, a method includes selecting a buffer system comprising a selected amount of arginine and a selected amount of 2-(N-cyclohexylamino)ethanesulfonic acid (CHES). The method also includes adding the buffer system to an amplification mixture for amplifying one of nucleic acids or deoxynucleotides. The selected amount of arginine and the selected amount of CHES are sufficient to increase stability of the amplification mixture across a predetermined pH range. The method further includes lyophilizing a composition including the amplification mixture and the buffer system to form a lyophilized material that is consumable during processing of a biological sample.
[0070] Any single one or any combination of the following features may be used with the fourth implementation.
[0071] In various forms of the fourth implementation, the selected amount of the arginine is between 0 to about 200 millimolar (mM) and the selected amount of CHES is between 0 and about 200 mM.
[0072] In various forms of the fourth implementation, the selected amount of the arginine is between about 10 to about 80 mM and the selected amount of CHES is between 0 and about 200 mM.
[0073] In various forms of the fourth implementation, the selected amount of the arginine is between 0 to about 200 mM and the selected amount of CHES is between 10 and about 80 mM.
[0074] In various forms of the fourth implementation, the selected amount of the arginine is 0 mM and the selected amount of CHES is between about 20 and about 180 mM.
[0075] In various forms of the fourth implementation, the selected amount of CHES is between about 20 and about 80 mM.
[0076] In various forms of the fourth implementation, the selected amount of CHES is between about 40 and about 80 mM.
[0077] In various forms of the fourth implementation, the predetermined pH range is up to and includes 0.9 pH units.
[0078] In various forms of the fourth implementation, the predetermined pH range is at least 0.5 pH units.
[0079] In various forms of the fourth implementation, at least a portion of the predetermined pH range falls within pH 8.59 to pH 9.59.
[0080] In various forms of the fourth implementation, the buffer system further increases glass transition temperature of the lyophilized material.
[0081] In various forms of the fourth implementation, the buffer system further increases stability’ of one or more nucleotides present within the amplification mixture.
[0082] In various forms of the fourth implementation, the buffer system further thermally stabilizes one or more enzymes within the amplification mixture.
[0083] In various forms of the fourth implementation, the arginine further promotes one of amplification efficiency or amplification accuracy of the amplification mixture.
[0084] In various forms of the fourth implementation, the amplification mixture comprises an elongation polymerase.
[0085] In various forms of the fourth implementation, the elongation polymerase is thermostable and retains resistance to thermal denaturation based on presence of the arginine.
[0086] In various forms of the fourth implementation, the lyophilized material has an appearance of homogeneity.
[0087] In various forms of the fourth implementation, the lyophilized material produces a substantially homogenous mixture when rehydrated.
[0088] In various forms of the fourth implementation, the lyophilized material comprises a cake.
[0089] In a fifth implementation, a method includes providing a receptacle containing a lyophilized material that is consumable during processing of a biological sample. The lyophilized material includes a buffer system and an amplification mixture for amplifying one of nucleic acids or deoxynucleotide triphosphates (dNTPs). The buffer system includes a selected amount of arginine and a selected amount of 2-(N-cyclohexylamino)ethanesulfonic acid (CHES). The selected amount of arginine and the selected amount of CHES are sufficient to increase stability of the amplification mixture across a predetermined pH range. The method also includes rehydrating the lyophilized material to form a liquid reagent mixture for a sequencing process in the receptacle.
[0090] Any single one or any combination of the following features may be used with the fifth implementation.
[0091] In various forms of the fifth implementation, the method includes adding a portion of the liquid reagent mixture from the receptacle to a test site for a biological sample.
[0092] In various forms of the fifth implementation, the selected amount of the arginine is between 0 to about 200 millimolar (mM) and the selected amount of CHES is between 0 and about 200 mM.
[0093] In various forms of the fifth implementation, the selected amount of the arginine is between about 10 to about 80 mM and the selected amount of CHES is between 0 and about 200 mM.
[0094] In various forms of the fifth implementation, the selected amount of the arginine is between 0 to about 200 mM and the selected amount of CHES is between 10 and about 80 mM.
[0095] In various forms of the fifth implementation, the selected amount of the arginine is 0 mM and the selected amount of CHES is between about 20 and about 180 mM.
[0096] In various forms of the fifth implementation, the selected amount of CHES is between about 20 and about 80 mM.
[0097] In various forms of the fifth implementation, the selected amount of CHES is between about 40 and about 80 mM.
[0098] In various forms of the fifth implementation, the predetermined pH range is up to and includes 0.9 pH units.
[0099] In various forms of the fifth implementation, the predetermined pH range is at least 0.5 pH units.
[0100] In various forms of the fifth implementation, at least a portion of the predetermined pH range falls within pH 8.59 to pH 9.59.
[0101] In various forms of the fifth implementation, the buffer system further increases glass transition temperature of the lyophilized material.
[0102] In various forms of the fifth implementation, the buffer system further increases stability of one or more nucleotides present within the amplification mixture.
[0103] In various forms of the fifth implementation, the buffer system further thermally stabilizes one or more enzymes within the amplification mixture.
[0104] In various forms of the fifth implementation, the arginine further promotes one of amplification efficiency or amplification accuracy of the amplification mixture.
[0105] In various forms of the fifth implementation, the amplification mixture comprises an elongation polymerase.
[0106] In various forms of the fifth implementation, the elongation polymerase is thermostable and retains resistance to thermal denaturation based on presence of the arginine.
[0107] In various forms of the fifth implementation, the lyophilized material has an appearance of homogeneity.
[0108] In various forms of the fifth implementation, the lyophilized material produces a substantially homogenous mixture when rehydrated.
[0109] In various forms of the fifth implementation, the lyophilized material comprises a cake.
[0110] In various forms of the fifth implementation, the method includes mixing the liquid reagent mixture with an analyte.
[0111] In various forms of the fifth implementation, the analyte comprises one or more nucleic acid samples.
[0112] In various forms of the fifth implementation, the method includes determining a nucleotide of a sequence for the analyte.
[0113] In various forms of the fifth implementation, the method includes determining a nucleotide of a sequence for the analyte.
[0114] In various forms of the fifth implementation, the method includes cleaving a chemical blocker from the analyte.
[0115] In various forms of the fifth implementation, the method includes flowing the liquid reagent mixture through a flow cell having a plurality of reaction sites.
[0116] In various forms of the fifth implementation, the plurality of reaction sites comprise strands of one or more nucleotides.
[0117] In various forms of the fifth implementation, each of the plurality of reaction sites comprises a clonal cluster of strands of nucleotides.
[0118] In a sixth implementation, a consumable product includes a receptacle and a lyophilized material within the receptacle that is consumable during processing of a biological sample. The lyophilized material includes an amplification mixture for amplifying one of nucleic acids or deoxynucleotide triphosphates (dNTPs), and a buffer system including a selected amount of arginine and a selected amount of 2-(N-cyclohexylamino)ethanesulfonic acid (CHES). The selected amount of arginine and the selected amount of CHES are sufficient to increase stability of the amplification mixture across a predetermined pH range. Rehydration of the lyophilized material forms a liquid reagent mixture for a sequencing process in the receptacle.
[0119] Any single one or any combination of the following features may be used with the sixth implementation.
[0120] In various forms of the sixth implementation, the receptacle includes an opening for removing a portion of the liquid reagent mixture from the receptacle to add to a test site for a biological sample.
[0121] In various forms of the sixth implementation, the selected amount of the arginine is between 0 to about 200 millimolar (mM) and the selected amount of CHES is between 0 and about 200 mM.
[0122] In various forms of the sixth implementation, the selected amount of the arginine is between about 10 to about 80 mM and the selected amount of CHES is between 0 and about 200 mM.
[0123] In various forms of the sixth implementation, the selected amount of the arginine is between 0 to about 200 mM and the selected amount of CHES is between 10 and about 80 mM.
[0124] In various forms of the sixth implementation, the selected amount of the arginine is 0 mM and the selected amount of CHES is between about 20 and about 180 mM.
[0125] In various forms of the sixth implementation, the selected amount of CHES is between about 20 and about 80 mM.
[0126] In various forms of the sixth implementation, the selected amount of CHES is between about 40 and about 80 mM.
[0127] In various forms of the sixth implementation, the predetermined pH range is up to and includes 0.9 pH units.
[0128] In various forms of the sixth implementation, the predetermined pH range is at least 0.5 pH units.
[0129] In various forms of the sixth implementation, at least a portion of the predetermined pH range falls within pH 8.59 to pH 9.59.
[0130] In various forms of the sixth implementation, the buffer system further increases glass transition temperature of the lyophilized material.
[0131] In various forms of the sixth implementation, the buffer system further increases stability of one or more nucleotides present within the amplification mixture.
[0132] In various forms of the sixth implementation, the buffer system further thermally stabilizes one or more enzymes within the amplification mixture.
[0133] In various forms of the sixth implementation, the arginine further promotes one of amplification efficiency or amplification accuracy of the amplification mixture.
[0134] In various forms of the sixth implementation, the amplification mixture comprises an elongation polymerase.
[0135] In various forms of the sixth implementation, the elongation polymerase is thermostable and retains resistance to thermal denaturation based on presence of the arginine.
[0136] In various forms of the sixth implementation, the lyophilized material has an appearance of homogeneity.
[0137] In various forms of the sixth implementation, the lyophilized material produces a substantially homogenous mixture when rehydrated.
[0138] In various forms of the sixth implementation, the lyophilized material comprises a cake.
[0139] In a seventh implementation, a composition includes a lyophilized material for processing a biological sample. The lyophilized material includes an amplification mixture for amplifying one of nucleic acids or deoxynucleotide triphosphates (dNTPs), and a buffer system comprising a selected amount of arginine and a selected amount of 2-(N-cyclohexylamino)ethanesulfonic acid (CHES). The selected amount of arginine and the selected amount of CHES are sufficient to increase stability of the amplification mixture across a predetermined pH range.
[0140] Any single one or any combination of the following features may be used with the seventh implementation.
[0141] In various forms of the seventh implementation, the selected amount of the arginine is between 0 to about 200 millimolar (mM) and the selected amount of CHES is between 0 and about 200 mM.
[0142] In various forms of the seventh implementation, the selected amount of the arginine is between about 10 to about 80 mM and the selected amount of CHES is between 0 and about 200 mM.
[0143] In various forms of the seventh implementation, the selected amount of the arginine is between 0 to about 200 mM and the selected amount of CHES is between 10 and about 80 mM.
[0144] In various forms of the seventh implementation, the selected amount of the arginine is 0 mM and the selected amount of CHES is between about 20 and about 180 mM.
[0145] In various forms of the seventh implementation, the selected amount of CHES is between about 20 and about 80 mM.
[0146] In various forms of the seventh implementation, the selected amount of CHES is between about 40 and about 80 mM.
[0147] In various forms of the seventh implementation, the predetermined pH range is up to and includes 0.9 pH units.
[0148] In various forms of the seventh implementation, the predetermined pH range is at least 0.5 pH units.
[0149] In various forms of the seventh implementation, at least a portion of the predetermined pH range falls within pH 8.59 to pH 9.59.
[0150] In various forms of the seventh implementation, the buffer system further increases glass transition temperature of the lyophilized material.
[0151] In various forms of the seventh implementation, the buffer system further increases stability’ of one or more nucleotides present within the amplification mixture.
[0152] In various forms of the seventh implementation, the buffer system further thermally stabilizes one or more enzymes within the amplification mixture.
[0153] In various forms of the seventh implementation, the arginine further promotes one of amplification efficiency or amplification accuracy of the amplification mixture.
[0154] In various forms of the seventh implementation, the amplification mixture comprises an elongation polymerase.
[0155] In various forms of the seventh implementation, the elongation polymerase is thermostable and retains resistance to thermal denaturation based on presence of the arginine.
[0156] In various forms of the seventh implementation, the lyophilized material has an appearance of homogeneity.
[0157] In various forms of the seventh implementation, the lyophilized material produces a substantially homogenous mixture when rehydrated.
[0158] In various forms of the seventh implementation, the lyophilized material comprises a cake.
[0159] In an eighth implementation, a method includes providing a receptacle containing a lyophilized material that is consumable during processing of a biological sample, the lyophilized material comprising a buffer system and an amplification mixture for amplifying one of nucleic acids or deoxynucleotide triphosphates (dNTPs). The buffer system includes a selected amount of 2-(N-cyclohexylamino)ethanesulfonic acid (CHES). The selected amount of CHES is sufficient to increase stability of the amplification mixture across a predetermined pH range. The method also includes rehydrating the lyophilized material to form a liquid reagent mixture for a sequencing process in the receptacle.
[0160] Any single one or any combination of the following features may be used with the eighth implementation.
[0161] In various forms of the eighth implementation, the method includes adding a portion of the liquid reagent mixture from the receptacle to a test site for a biological sample.
[0162] In various forms of the eighth implementation, the selected amount of CHES is between 0 and about 200 millimolar (mM).
[0163] In various forms of the eighth implementation, the selected amount of CHES is between 10 and about 80 mM.
[0164] In various forms of the eighth implementation, the selected amount of CHES is between about 20 and about 180 mM.
[0165] In various forms of the eighth implementation, the selected amount of CHES is between about 20 and about 80 mM.
[0166] In various forms of the eighth implementation, the selected amount of CHES is between about 40 and about 80 mM.
[0167] In various forms of the eighth implementation, the predetermined pH range is up to and includes 0.9 pH units.
[0168] In various forms of the eighth implementation, the predetermined pH range is at least 0.5 pH units.
[0169] In various forms of the eighth implementation, at least a portion of the predetermined pH range falls within pH 8.59 to pH 9.59.
[0170] In various forms of the eighth implementation, the buffer system further increases glass transition temperature of the lyophilized material.
[0171] In various forms of the eighth implementation, the buffer system further increases stabi 1 ity of one or more nucleotides present within the amplification mixture.
[0172] In various forms of the eighth implementation, the CHES further promotes one of amplification efficiency or amplification accuracy of the amplification mixture.
[0173] In various forms of the eighth implementation, the amplification mixture comprises an elongation polymerase.
[0174] In various forms of the eighth implementation, the elongation polymerase is thermostable and retains resistance to thermal denaturation based on presence of the CHES.
[0175] In various forms of the eighth implementation, the lyophilized material has an appearance of homogeneity.
[0176] In various forms of the eighth implementation, the lyophilized material produces a substantially homogenous mixture when rehydrated.
[0177] In various forms of the eighth implementation, the lyophilized material comprises a cake.
[0178] In various forms of the eighth implementation, the method includes mixing the liquid reagent mixture with an analyte.
[0179] In various forms of the eighth implementation, the analyte comprises one or more nucleic acid samples.
[0180] In various forms of the eighth implementation, the method includes determining a nucleotide of a sequence for the analyte.
[0181] In various forms of the eighth implementation, the method includes cleaving a chemical blocker from the analyte.
[0182] In various forms of the eighth implementation, the method includes flowing the liquid reagent mixture through a flow cell having a plurality of reaction sites.
[0183] In various forms of the eighth implementation, the plurality of reaction sites comprises strands of one or more nucleotides.
[0184] In various forms of the eighth implementation, the strands of one or more nucleotides comprise a clonal cluster of strands of different nucleotides among the one or more nucleotides at different reaction sites among the plurality' of reaction sites.
[0185] In various forms of the eighth implementation, each of the plurality of reaction sites comprises a clonal cluster of strands of nucleotides.
[0186] Other technical features may be readily apparent to one skilled in the art from the following figures, descriptions, and claims.
[0187] Unless defined otherwise herein, all technical and scientific terms used herein have the meaning as commonly understood by one of ordinary skill in the art within the context of the disclosure, and in the specific context where each term is used. It will further be understood that common terms and phrases, such as those defined in commonly-used dictionaries, should be interpreted as having a meaning that is consistent with their meaning in the context of the relevant art and should not be interpreted in an idealized or overly formal sense unless expressly so defined here. However, so that the present disclosure may be more readily understood, before undertaking the DETAILED DESCRIPTION below, it may be advantageous to set forth definitions of certain words and phrases used throughout this patent document. Therefore, certain terms are first defined, and additional definitions are set forth throughout the document.
[0188] The terms '“include’7and ““comprise,” as well as derivatives thereof, mean inclusion without limitation. The term “or” is inclusive, meaning and / or. The phrase “associated with,” as well as derivatives thereof, means to include, be included within, interconnect with, contain, be contained within, connect to or with, couple to or with, be communicable with, cooperate with, interleave, juxtapose, be proximate to, be bound to or with, have, have a property of, have a relationship to or with, or the like.
[0189] As used here, terms and phrases such as “have,” ‘“may have,” “include,” or “may include” a feature (like a number, function, operation, or component such as a part) indicate the existence of the feature and do not exclude the existence of other features. Also, as used here, the phrases “A or B,” “at least one of A and / or B,” or “one or more of A and / or B” may include all possible combinations of A and B. For example, “A or B,” “at least one of A and B,” and “at least one of A or B” may indicate all of (i) including at least one A, (ii) including at least one B, or (iii) including at least one A and at least one B. Further, as used here, the terms “first” and “second”may modify various components regardless of importance and do not limit the components. These terms are only used to distinguish one component from another. For example, a first user device and a second user device may indicate different user devices from each other, regardless of the order or importance of the devices. A first component may be denoted a second component and vice versa without departing from the scope of this disclosure.
[0190] It will be understood that, when an element (such as a first element) is referred to as being (operatively or communicatively) “coupled with / to” or “connected with / to’' another element (such as a second element), it can be coupled or connected with / to the other element directly or via a third element. In contrast, it will be understood that, when an element (such as a first element) is referred to as being “directly coupled with / to” or “directly connected with / to” another element (such as a second element), no other element (such as a third element) intervenes between the element and the other element.
[0191] The terms “connect,” “connected,” “coupled,” and / or the like are broadly defined herein to encompass a variety of divergent arrangements and assembly techniques. These arrangements and techniques include, but are not limited to, (i) the direct joining of one component and another component with no intervening components therebetween (such as the components are in direct physical contact); and (ii) the joining of one component and another component with one or more components therebetween, provided that the one component being “connected to” or “coupled to” the other component is somehow in operative communication (such as electrically, fluidly, physically, optically, etc.) with the other component (notwithstanding the presence of one or more additional components therebetween). By contrast, the term “contact” or “contacting” refers to the direct joining, connection, or contiguous arrangement of one component and another component with no intervening components therebetween. It is to be understood that some components that are in direct physical contact with one another may or may not be in electrical contact and / or fluid contact with one another. Moreover, two components that are electrically connected, electrically coupled, optically connected, optically coupled, fluidly connected, or fluidly coupled may or may not be in direct physical contact, and one or more other components may be positioned therebetween.
[0192] As used here, the phrase “configured for” (or “configured to” or “set to”) may be interchangeably used with the phrases “suitable for,” “having the capacity to,” “designed to,” “adapted to,” “made to,” or “capable of’ depending on the circumstances. The phrase “configured (or set) to” does not essentially mean “specifically designed in hardware to.” Rather, the phrase “configured to” may mean that a device can perform an operation together with another device or parts. For example, the phrase “processor configured (or set) to perform A, B, and C” may mean ageneric-purpose processor (such as a CPU or application processor) that may perform the operations by executing one or more software programs stored in a memory' device or a dedicated processor (such as an embedded processor) for performing the operations.
[0193] The terms and phrases as used here are provided merely to describe some implementations of this disclosure but not to limit the scope of other implementations of this disclosure. It is to be understood that the singular forms “a,” “an,” and “the” include plural references unless the context clearly dictates otherwise. The term “plurality ” refers to more than one element. That is, as used herein, the term “plurality” is intended to mean a population of two or more different members. Pluralities can range in size from small, medium, large, to very' large. The size of small plurality can range, for example, from a few members to tens of members. Medium sized pluralities can range, for example, from tens of members to about 100 members or hundreds of members. Large pluralities can range, for example, from about hundreds of members to about 1000 members, to thousands of members and up to tens of thousands of members. Very large pluralities can range, for example, from tens of thousands of members to about hundreds of thousands, a million, millions, tens of millions and up to or greater than hundreds of millions of members. Therefore, a plurality can range in size from two to well over one hundred million members as well as all sizes, as measured by the number of members, in between and greater than the above example ranges. An example number of features within a microarray includes a plurality of about 500,000 or more discrete features within 1.28 square centimeters (cm2). Example nucleic acid pluralities include, for example, populations of about l*103, 5xl03and l*106or more different nucleic acid species. Accordingly, the definition of the term is intended to include all integer values greater than two. An upper limit of a plurality can be set, for example, by the theoretical diversity of nucleotide sequences in a nucleic acid sample.
[0194] The terms “substantially,” “approximately,” “about,” “relatively,” or other such similar terms that may be used throughout this disclosure, including the claims, are used to describe and account for small fluctuations, such as due to variations in processing, from a reference or parameter. Such small fluctuations include a zero fluctuation from the reference or parameter as well. For example, fluctuations can refer to less than or equal to ±10%, such as less than or equal to ±5%, such as less than or equal to ±2%, such as less than or equal to ±1%, such as less than or equal to ±0.5%, such as less than or equal to ±0.2%, such as less than or equal to ±0.1%, such as less than or equal to ±0.05%.
[0195] Definitions for other certain words and phrases may be provided throughout this document. Those of ordinary' skill in the art should understand that in many if not most instances, such definitions apply to prior as well as future uses of such defined words and phrases. In somecases, the terms and phrases defined here may be interpreted to exclude implementations of this disclosure.
[0196] None of the description in this application should be read as implying that any particular element, step, or function is an essential element that must be included in the claim scope. The scope of patented subject matter is defined only by the claims. Moreover, none of the claims is intended to invoke 35 U.S.C. § 112(f) unless the exact words “means for” are followed by a participle. Use of any other term, including without limitation “mechanism,” “module,” “device,” “unit,” “component,” “element,” “member,” “apparatus,” “machine,” “system,” “processor,” or “controller,” within a claim is understood by the Applicant to refer to structures known to those skilled in the relevant art and is not intended to invoke 35 U.S.C. § 112(f).BRIEF DESCRIPTION OF THE DRAWINGS
[0197] For a more complete understanding of this disclosure and its advantages, reference is now made to the following description taken in conjunction with the accompanying drawings, in which like reference numerals represent like parts:
[0198] FIGS. 1 through 3 collectively illustrate an example screening process indicating that arginine suitably serves a pH buffer function in connection with lyophilized PCR reagents according to this disclosure;
[0199] FIGS. 4A and 4B illustrate example characteristics of arginine as a function of pH according to this disclosure;
[0200] FIG. 5 illustrates PCR performance of an example formulation using an arginine buffer in cycle threshold (Ct) values as a function of pH according to this disclosure;
[0201] FIG. 6 illustrates example glass transition temperature for various excipients in the presence of an arginine buffer according to this disclosure;
[0202] FIG. 7 illustrates example nucleotide stabili ty of an arginine-based formulation according to this disclosure;
[0203] FIG. 8 illustrates PCR performance of an example formulation using a CHES buffer in cycle threshold (Ct) values as a function of pH, analogous to FIG. 5;
[0204] FIGS. 9A-9C illustrate example glass transition temperature Tg' for various excipients in the presence of different buffers, analogous to FIG. 6;
[0205] FIG. 10 illustrates median glass transition temperature Tg' for the different buffers of FIGS. 9A-9C;
[0206] FIG. 11 illustrates robustness of arginine- and CHES-based crude formulations to freeze / thaw stress;
[0207] FIGS. 12A and 12B illustrate key properties of CHES-based liquid formulations, relative to lyophilization in cake form;
[0208] FIG. 13 illustrates titration of arginine in CHES-based formulations according to the present disclosure;
[0209] FIG. 14 illustrates PCR performance, expressed as Ct value, for the PCR master mixtures of FIG. 13;
[0210] FIGS. 15A through 15D are images of microspheres generated with a CHES-based buffer formulation;
[0211] FIG. 16 is a plot of the size and distribution of microspheres generated with a formulation containing CHES;
[0212] FIG. 17 illustrates the how much of the original amount of adenosine triphosphate is successfully preserved during storage for cakes with a CHES-based buffer;
[0213] FIG. 18 illustrates that formulations using an A-Tailing mixture with a CHES-based buffer are well lyophilized;
[0214] FIG. 19 illustrates that the CHES-based A-Tailing mixture results in slower small molecule degradation; and
[0215] FIGS. 20A and 20B illustrate impact of the CHES-based buffer in the A-Tailing mixture on functional workflow and performance, relative to a control.DETAILED DESCRIPTION
[0216] FIGS. 1 through 20B, described below, and the various implementations used to describe the principles of the present disclosure are by way of illustration only and should not be construed in any way to limit the scope of this disclosure. Those skilled in the art will understand that the principles of the present disclosure may be implemented in any t pe of suitably arranged device or system.
[0217] NGS (defined herein) includes sample pre-processing and library preparation as process elements. These process elements remain lengthy, multi-step, low-throughput processes. Library preparation can be an important or essential process with several aspects that affect the efficiency of NGS. Reliable and standardized implementation and quality control measures of the process are necessary or desirable for these process elements.
[0218] Challenges can be encountered at each of the workflow steps, and benefits and advantages may be realized by tackling these challenges to enable high-quality sequencing results. During library preparation, for example, major challenges can be observed: complexity of the protocols; imprecise pipetting; contamination; and cost. Sample contamination is an inherentproblem since libraries are usually prepared in parallel. Major sources of contamination can include the pre-amplifications usually involved with low starting concentrations of nucleic acids. Multiple liquid-handling steps also increase the risk of sample cross-contamination. Repetitive pipetting or repetitive heating may also lead to degradation of nucleic acids.
[0219] Standard workflows are thus both complex and often expensive, usually requiring expensive laboratory equipment and reagents together with trained personnel, and usually also involving many liquid-handling steps. Therefore, even as the cost of data acquisition (sequencing) continues to decrease, for many large-scale genomic experiments, sample acquisition, sample storage and the requisite cold chain, sample pre-processing, and library preparation for sequencing create a time, cost, and labor bottleneck. The bottleneck represents a severe constraint in resourcelimited settings. As current technologies allow7for sequencing millions or billions of DNA fragments in parallel at relatively low costs, the scope of data generation is often limited by difficulties in sample preparation rather than sequencing capacity.
[0220] The present disclosure addresses these or other shortcomings by providing consumables that facilitate nucleic acid analysis. As used herein, “consumable” includes any component that is used up recurrently and may need to be replaced to function as intended. In some cases, consumables may be single-use components involving disposal subsequent to use. Biological sample collection containers, for instance, are consumables that are often fabricated as sterile glass or plastic tubes configured to facilitate the collection of a predetermined volume of liquid, where the container is or is capable of being sealed subsequent to sample collection. Such biological sample collection containers may include, within the container, predetermined quantities of reagents or other biological sample processing components in the form of coatings, particles, or the like. The reagents or other biological sample processing components may be selected, for example, to stabilize a collected biological sample. The reagents or other biological sample processing components within a biological sample collection container can form part of the same consumable.
[0221] Depending on the implementation, the consumables described in the present disclosure have many benefits. This may include, for example, stabilization of samples and / or reagents, reducing or eliminating the need for cold transportation and storage, enabling or improving room temperature shipping and storage of samples and / or reagents and complete assays, reducing plastic waste, and resistance of the encapsulated lyophilized reagent microspheres to harsh environmental conditions.
[0222] The present disclosure also relates to consumables involved in collection or preparation of biological samples for processing. The term “sample” herein refers to a sample,typically derived from a biological fluid, cell, tissue, organ, or organism containing a nucleic acid or a mixture of nucleic acids containing at least one nucleic acid sequence that is to be sequenced and / or phased and / or containing proteins or other materials that can be assayed. Such samples include, but are not limited to, sputum / oral fluid, amniotic fluid, blood, a blood fraction, a fine needle biopsy sample (such as a surgical biopsy, fine needle biopsy, etc.), urine, peritoneal fluid, pleural fluid, tissue explant, organ culture, and any other tissue or cell preparation, or fraction or derivative thereof or isolated therefrom. As used herein, the terms “blood,'’ “plasma,” and “serum” expressly encompass fractions or processed portions thereof. Similarly, where a sample is taken from a biopsy, swab, smear, etc., the “sample” expressly encompasses a processed fraction or portion derived from the biopsy, swab, smear, etc.
[0223] Although the sample is often taken from a human subject (such as a patient), samples can come from other sources. For example, samples can be taken from any organism having nucleic acid sequences, including, but not limited to, dogs, cats, horses, goats, sheep, cattle, pigs, com, soy, bacteria, viruses, environmental DNA (eDNA), etc. The sample may be used directly as obtained from the biological source or following a pretreatment to modify the character of the sample. For example, such pretreatment may include preparing plasma from blood, diluting viscous fluids, and so forth. Methods of pretreatment may also involve, but are not limited to, filtration, precipitation, dilution, distillation, mixing, centrifugation, freezing, lyophilization, concentration, amplification, nucleic acid fragmentation, inactivation of interfering components, the addition of reagents, lysing, etc. If such methods of pretreatment are employed with respect to the sample, such pretreatment methods are typically such that the nucleic acid(s) of interest remain in the test sample, sometimes at a concentration proportional to that in an untreated test sample (such as a sample that is not subjected to any such pretreatment method(s)). Such “treated” or “processed” samples are still considered to be biological “test” samples with respect to the compositions, systems, and methods described herein.
[0224] A sample can be a primary cell culture or culture adapted cell line including, but not limited to, genetically-engineered cell lines that may contain chromosomally integrated or episomal recombinant nucleic acid sequences, immortalized or immortalizable cell lines, somatic cell hybrid cell lines, differentiated or differentiatable cell lines, transformed cell lines, stem cells, germ cells (such as sperm, oocytes), transformed cell lines, and the like. For example, polynucleotide molecules may be obtained from primary cells, cell lines, freshly-isolated cells or tissues, frozen cells or tissues, paraffin-embedded cells or tissues, fixed cells or tissues, and / or laser-dissected cells or tissues. Biological samples can be obtained from any subject or biological source, including, but not limited to, human or non-human animals, including mammals and non-mammals, vertebrates and invertebrates. Biological samples may also be any multicellular organism or single-celled organism, such as eukaryotic (including plants and algae) or prokaryotic organisms, archaeon, microorganisms (such as bacteria, archaea, fungi, protists, and viruses), and aquatic plankton.
[0225] The terms “polynucleotide,’’ “nucleic acid,” and “nucleic acid molecules” are used interchangeably and refer to a covalently-linked sequence of nucleotides (such as ribonucleotides for RNA and deoxy ribonucleotides for DNA) in which the 3’ position of the pentose of one nucleotide is joined by a phosphodiester group to the 5’ position of the pentose of the next. The nucleotides include sequences of any form of nucleic acid, including, but not limited to, RNA and DNA molecules such as cfRNA and cfDNA molecules, circulating tumor RNA (ctRNA) and circulating tumor DNA (ctDNA) molecules, cell-free fetal DNA (cffDNA) molecules, and environmental DNA (eDNA) molecules. The term “polynucleotide” includes, without limitation, single- and double-stranded polynucleotide. The terms as used herein also encompasses cDNA that is complementary or copy DNA, produced from an RNA template, such as by the action of reverse transcriptase. In some implementations, the nucleic acid to be analyzed, such as by sequencing through use of the described systems, is immobilized on a substrate (like a substrate within a flow cell or one or more beads upon a substrate such as a flow cell. etc.). The term immobilized as used herein is intended to encompass direct or indirect, covalent, or non-covalent attachment, unless indicated otherwise either explicitly or by context. The analytes (such as nucleic acids) may remain immobilized or attached to the support under conditions in which it is intended to use the support, such as in nucleic acid sequencing applications. In some implementations, the template polynucleotide is one of a plurality of template polynucleotides attached to a substrate. In some implementations, the plurality of template polynucleotides attached to the substrate includes a cluster of copies of a library polynucleotide.
[0226] Nucleic acids include naturally-occurring nucleic acids or functional analogs thereof. Particularly useful functional analogs are capable of hybridizing to a nucleic acid in a sequence-specific fashion or are capable of being used as a template for replication of a particular nucleotide sequence. The nucleic acid described herein can be of any length suitable for use in the provided compositions, systems, and methods. For example, target nucleic acids can be at least 10 kilobase (kb), at least 20 kb, at least 30 kb. at least 40 kb, at least 50 kb, at least 75 kb, at least 100 kb, at least 150 kb, at least 200 kb, at least 250 kb, at least 500 kb, or at least 1000 kb in length or longer.
[0227] The term “Next Generation Sequencing” (NGS) herein refers to sequencing methods that allow for massively parallel sequencing of clonally-amplified molecules and of singlenucleic acid molecules. Non-limiting examples of NGS include sequencing-by-synthesis (SBS) using reversible dye terminators, sequencing-by-ligation, and nanopore sequencing. The phrase “processing of a biological sample” includes any process relating to nucleic acid analysis, such as (but not limited to) nucleic acid sequencing, genotyping, sample preparation, and library preparation.
[0228] The term “library” refers to a collection or plurality of nucleic acid template molecules that have a common use or common property, such as a common origin; an example may include when all members of the library come from a single sample. The members of the library may be processed or modified so that their membership in the library is clearly identified. For example, all members of a library may share a common sequence at their 5’ ends and a common sequence at their 3’ ends. Use of the term "library" to refer to a collection or plurality of template molecules should not be taken to imply that the templates making up the library' are derived from a particular source or that the “library” has a particular composition. By way of example, use of the term “library” should not be taken to imply that the individual templates within the library must be of different nucleotide sequence or that the templates be related in terms of sequence and / or source.
[0229] The terms “address,” “index,” “index sequence,” “unique identifier,” “barcode,” “barcode sequence,” and “tag” are used interchangeably herein unless specified otherwise. The terms refer to a sequence of nucleotides, such as oligonucleotides, that can be used to identity a sequence of interest, such as region of a genome or haplotype. The address, index, index sequence, unique identifier, barcode, barcode sequence, or tag sequence may be exogenously incorporated into the sequence of interest by ligation, extension, or other methods known in the art. The index sequence may also be endogenous to the sequence of interest, such as when a segment in the sequence of interest itself may be used as an index. A nucleotide address, index, index sequence, unique identifier, barcode, barcode sequence, or tag can be a random or a specifically-designed nucleotide sequence. An address, index, index sequence, unique identifier, barcode, barcode sequence, or tag can be of any desired sequence length so long as it is of sufficient length to be a unique nucleotide sequence within a plurality of indices in a population and / or within a plurality of polynucleotides that are being analyzed or interrogated. A nucleotide address, index, index sequence, unique identifier, barcode, barcode sequence, or tag is useful, for example, to be attached to a target polynucleotide to tag or mark a particular species for identifying all members of the tagged species within a population. Accordingly, an index is useful as a barcode where different members of the same molecular species can contain the same index and where different species within a population of different polynucleotides can have different indices.
[0230] As used herein, the term “target nucleic acid” is intended to mean a nucleic acid that is the object of an analysis or action. The analysis or action may include subjecting the nucleic acid to copying, amplification, sequencing, and / or other procedure for nucleic acid interrogation. A target nucleic acid can include nucleotide sequences additional to the target sequence to be analyzed. For example, a target nucleic acid can include one or more adapters, including an adapter that functions as a primer binding site, that flank(s) a target nucleic acid sequence that is to be analyzed. A target nucleic acid hybridized to a capture oligonucleotide or capture primer can contain nucleotides that extend beyond the 5' or 3' end of the capture oligonucleotide in such a way that not all of the target nucleic acid is amenable to extension.
[0231] As used herein, the term “substrate” is intended to mean a solid or semi-solid support or support structure. The term includes any material that can serve as a solid or semi -solid foundation for creation of features such as wells for the deposition of biopolymers, including nucleic acids, polypeptides, and / or other polymers. Non-limiting examples of substrates include a bead array, a spotted array, clustered particles arranged on a surface of a chip, a film, a multi-well plate, a cartridge, and a flow cell. A substrate as provided herein is modified or can be modified, for example, to accommodate attachment of biopolymers by a variety' of methods well known to those skilled in the art. Example types of substrate materials include glasses, modified glasses, functionalized glasses, inorganic glasses, spheres (including inert and / or magnetic particles, as well as microspheres, lyospheres, and encapsulated microspheres as those terms are defined herein), plastics, polysaccharides, nylon, nitrocellulose, ceramics, resins, silica, silica-based materials, carbon, metals, optical fibers or optical fiber bundles, a variety of polymers other than those described above, and multi-well microtiter plates. Specific types of example plastics include acrylics, polystyrene, copolymers of styrene and other materials, polypropylene, polyethylene, polybutylene, polyurethanes, and TEFLON. Specific types of example silica-based materials include silicon and various forms of modified silicon.
[0232] In some implementations, the solid or semi-solid support includes one or more surfaces that are accessible to contact with reagents, beads, or analytes. The surface can be substantially flat or planar. Alternatively, the surface can be rounded or contoured. Example contours that can be included on a surface are w ells (such as microwells or nanow ells), depressions, pillars, ridges, channels, or the like. Example materials that can be used as a surface include glasses; modified glasses; functionalized glasses; plastics such as acrylic, polystyrene, a copolymer of styrene and another material, polypropylene, polyethylene, polybutylene, polyurethane, or TEFLON; polysaccharides or cross-linked polysaccharides such as agarose or Sepharose; nylon; nitrocellulose; resins; silica or silica-based materials including silicon and modified silicon;carbon-fiber; metals; inorganic glasses; optical fibers or optical fiber bundles; or a variety of other polymers. A single material or mixture of several different materials can form a surface useful in certain examples. In some examples, a surface includes wells (such as microwells or nanowells). In some aspects, the surface includes wells in an array of wells (such as microwells or nanowells) on glass, silicon, plastic, or other suitable solid or semi-solid supports with patterned, covalently linked gel. In some examples, a fluid dispensing vessel such as a pipette is used to transfer materials into the wells. In some examples, a support structure can include one or more layers.
[0233] As used herein, the term “double-stranded,” when used in reference to a nucleic acid molecule, means that substantially all of the nucleotides in the nucleic acid molecule are hydrogen-bonded to a complementary nucleotide. A partially double-stranded nucleic acid can have at least 10%, 25%, 50%, 60%, 70%, 80%, 90%, or 95% of its nucleotides hydrogen bonded to a complementary nucleotide. As used herein, the term “single-stranded,” when used in reference to a nucleic acid molecule, means that essentially none of the nucleotides in the nucleic acid molecule are hydrogen-bonded to a complementary nucleotide.
[0234] As used herein, the term “dNTP” refers to deoxynucleoside triphosphates. NTP refers to ribonucleotide triphosphates. The purine bases (Pu) include adenine (A), guanine (G), and derivatives and analogs thereof. The pyrimidine bases (Py) include cytosine (C), thymine (T), uracil (U), and derivatives and analogs thereof. Examples of such derivatives or analogs, by way of illustration and not limitation, are those that are modified with a reporter group, biotinylated, amine modified, radiolabeled, alky lated, and the like and also include phosphorothioate, phosphite, ring atom modified derivatives, and the like. The reporter group can be a fluorescent group such as fluorescein, a chemiluminescent group such as luminol, a terbium chelator such as N-(hydroxyethyl) ethylenediaminetriacetic acid that is capable of detection by delayed fluorescence, and the like.
[0235] As used herein, the term “size selection” means a procedure during which a subpopulation of nucleic acid fragments, the majority of which have a number of nucleotides falling in a defined range, is selected from a population of nucleic acid fragments. Thus, the percentage of nucleic acid fragments having a number of nucleotides falling in the defined range increases.
[0236] As used herein, the term “protease” refers to a protein, polypeptide, or peptide exhibiting the ability to hydrolyze polypeptides or substrates having a polypeptide portion. The protease(s) provided in the present compositions, systems, and methods can be a single protease possessing broad specificity (ability- to replicate one target sequence over many). The present compositions, systems, and methods can use a mixture of various proteases. The proteasesprovided herein can be heat-labile and thus can be inactivated by heat. In certain implementations, the proteases provided herein can be inactivated at a temperature above about 35° C, 40° C, 45° C, 50° C, 55° C, 60° C. 65° C, 70° C, 75° C, 80° C, or above about 85° C. The proteases provided herein can digest chromatin proteins and other DNA-binding proteins to release naked genomic DNA and can also digest endogenous DNase to protect DNA from degradation. The proteases provided herein include, but are not limited to, serine proteases, threonine proteases, cysteine proteases, aspartate proteases, glutamic acid proteases, and metalloproteases. Typically, aspartic, glutamic and metallo-proteases activate a water molecule, which performs a nucleophilic attack on the peptide bond to hydrolyze that bond. Serine, threonine, and cysteine proteases typically use a nucleophilic residue to perform a nucleophilic attack to covalently link the protease to the substrate protein, releasing the first half of the product. This covalent acyl-enzyme intermediate is then hydrolyzed by activated water to complete catalysis by releasing the second half of the product and regenerating the free enzyme. An example protease used herein includes a serine protease isolated from a recombinant Bacillus strain. Example proteases used herein also include Proteinase K, subtilisin and variants thereof, including alcalase, alcalase 0.6L, alcalase 2.5L, ALK-enzyme, bacillopeptidase A, bacillopeptidase B, Bacillus subtilis alkaline proteinase bioprase, bioprase AL 15, bioprase APL 30, colistinase. subtilisin J, subtilisin S41, subtilisin Sendai, subtilisin GX, subtilisin E, subtilisin BL, genenase I, esperase, maxatase, thermoase PC 10, protease XXVII, thermoase, superase, subtilisin Carlsberg subtilisin DY, subtilopeptidase, SP 266, savinase 8.0L, savinase 4.0T, kazusase, protease VIII, opticlean, protin A 3L, savinase, savinase 16.0L, savinase 32.0 L EX, orientase 10B, protease S, serine endopeptidase. In particular implementations of the compositions, systems, and methods presented herein, a heat-labile protease such as Proteinase K and heat-labile variants thereof can be used.
[0237] As used herein, the term “protease inhibitor” refers to a substance, such as a compound, capable of at least partially reducing the ability of a protease to hydrolyze peptides. Examples of protease inhibitors known in the art that can be used with the present compositions, systems, and methods include, but are not limited to, FOCUS PROTEASEARREST protease inhibitor cocktail, PEFABLOC SC (4-(2-Aminoethyl)-benzolsulfonylfluorid-hydrochloride) (AEBSF) protease inhibitor, Aprotinin protease inhibitor, Bestatin protease inhibitor, Leupeptin protease inhibitor, Phenylmethylsulfonyl fluoride (PMSF) protease inhibitor, and tripeptidyl chloromethyl ketones (TCK / TPCK, TLCK, and E-64) protease inhibitors.
[0238] As used herein, the term “tagmentation” refers to the modification of DNA by a transposome complex including transposase enzyme complexed with adaptors including transposon end sequence. Tagmentation results in the simultaneous fragmentation of the DNA andligation of the adaptors to the 5’ ends of both strands of duplex fragments. Additional sequences can be added to the ends of the adapted fragments, such as by PCR, ligation, or any other suitable methodology known to those of skill in the art. As used herein, the term “transposome complex” (TSM) refers to a transposase enzyme noncovalently bound to a double-stranded nucleic acid. For example, the complex can be a transposase enzyme preincubated with double-stranded transposon DNA under conditions that support non-covalent complex formation. Double-stranded transposon DNA can include, without limitation, Tn5 DNA, a portion of Tn5 DNA (such as Tn5 recognition site), a transposon end composition, a mixture of transposon end compositions, or other doublestranded DNAs capable of interacting with a transposase such as the hyperactive Tn5 transposase.
[0239] As used herein, the term “transposition reaction” refers to a reaction where one or more transposons are inserted into target nucleic acids, such as at random sites or almost random sites. Components in a transposition reaction are a transposase and DNA oligonucleotides that exhibit the nucleotide sequences of a transposon, including the transferred transposon sequence and its complement (the non-transferred transposon end sequence) as well as other components used to form a functional transposition or transposome complex. The DNA oligonucleotides can further include additional sequences (such as adaptor or primer sequences) as needed or desired. In some implementations, the compositions, systems, and methods provided herein can employ a transposition complex formed by a hyperactive Tn5 transposase and a Tn5-type transposon end. However, any transposition system that is capable of inserting a transposon end in a random or in an almost random manner with sufficient efficiency to 5’- tag and fragment a target DNA for its intended purpose can be used in the present disclosure. Examples of transposition systems known in the art that can be used for the present compositions, systems, and methods include, but are not limited to, Staphylococcus aureus Tn552, bacterial insertion sequences, and retrotransposon of yeast.
[0240] The method for inserting a transposon end into a target sequence can be carried out in vitro using any suitable transposon system for which a suitable in vitro transposition system is available or that can be developed based on knowledge in the art. In general, a suitable in vitro transposition system for use in the compositions, systems, and methods provided herein uses, at a minimum, a transposase enzyme of sufficient purity7, sufficient concentration, and sufficient in vitro transposition activity and a transposon end with which the transposase forms a functional complex with the respective transposase that is capable of catalyzing the transposition reaction. Suitable transposase transposon end sequences that can be used in the disclosure include, but are not limited to, w ild-type, derivative, or mutant transposon end sequences that form a complex with a transposase chosen from among a wild-ty pe, derivative, or mutant form of the transposase.
[0241] As used herein, the term "transposase" refers to an enzyme that is capable of forming a functional complex with a transposon end-containing composition (such as transposons, transposon ends, and transposon end compositions) and catalyzing insertion or transposition of the transposon end-containing composition into the double-stranded target nucleic acid with which it is incubated, such as in an in vitro transposition reaction. A transposase as presented herein can also include integrases from retrotransposons and retroviruses. Transposases, transposomes and transposome complexes are generally known to those of skill in the art.
[0242] Although many implementations described herein may refer to Tn5 transposase and / or hyperactive Tn5 transposase, it will be appreciated that any transposition system that is capable of inserting a transposon end with sufficient efficiency to 5 ’-tag and fragment a target nucleic acid for its intended purpose can be used in the present disclosure. In particular implementations, a transposition system is capable of inserting the transposon end in a random or in an almost random manner to 5 '-tag and fragment the target nucleic acid.
[0243] As used herein, the term ‘’library of tagged nucleic acid fragments” refers to a collection or population of tagged nucleic acid fragments (such as di-tagged nucleic acid fragments) generated from a resource, such as whole genome, where the combination of the tagged nucleic acid fragments in the collection or population exhibits sequences that are qualitatively and / or quantitatively representative of the sequence of the resource from which the tagged nucleic acid fragments were generated, such as whole genome. It is possible that a library of tagged nucleic acid fragments does not contain a tagged nucleic fragment representing every sequence that is exhibited by the resource.
[0244] As used herein, the term “primer” is an oligonucleotide (“oligo”), generally with a free 3’-OH group that can be extended by a nucleic acid polymerase. For a template- dependent polymerase, generally at least the 3 ’-portion of the primer oligo is complementary to a portion of a template nucleic acid to which the oligo “binds” (or “complexes,” “anneals,” or “hybridizes”) by hydrogen bonding and other molecular forces to the template to give a primer / template complex for initiation of synthesis by a DNA polymerase and which is extended by the addition of covalently -bonded bases linked at its 3’-end that are complementary to the template in the process of DNA synthesis. The result is a primer extension product.
[0245] As used herein, the term “adaptor” or “adapter” are used interchangeably and can refer to an oligonucleotide that may be attached to the end of a nucleic acid. Adaptor sequences may include, but are not limited to, priming sites, the complement of a priming site, recognition sites for endonucleases, common sequences, and promoters. Adaptors may also incorporatemodified nucleotides that modify the properties of the adaptor sequence. For example, phosphorothioate groups may be incorporated in one of the adaptor strands.
[0246] Consumables described herein may include particles having a coating surrounding a core, where the core may include one or more lyophilized microspheres (such that the composition may include an encapsulated lyophilized microsphere). In connection with encapsulated particles, the terms “encapsulate,” “encapsulated,” and “encapsulation” include the enclosing of one or more microspheres as described herein. In accordance with the present disclosure, the compositions, systems, and methods described herein have many benefits including, for example, increasing stability' of microspheres. The compositions, systems, and methods described herein use encapsulation of particles that would otherwise be responsive to pH changes to stabilize these buffers and increase SBS performance. As used herein in connection with at least lyophilized microspheres, encapsulated lyophilized microspheres, or similar materials, the term “trigger” refers to rehydrating, activating, releasing, or otherwise making the component(s) therein available for interaction with other materials and / or the environment.
[0247] As used herein, the term “microsphere” includes a spherical particle that may include a core and optionally has a shell. A microsphere has a diameter of 0.1 micron (pm) to 1,000 pm. For example, a microsphere may have a diameter of about 0.1 pm. 0.5 pm, 1 pm, 10 pm, 20 pm, 30 pm, 40 pm, 50 pm, 60 pm, 70 pm, 80 pm, 90 pm, 100 pm, 150 pm, 200 pm, 300 pm, 400 pm, 500 pm, 600 pm, 700 pm, 800 pm, 900 pm, 1000 pm, or any diameter between about 0.1 pm and about 1,000 pm. In some implementations, an encapsulated microsphere has a diameter between about 100 pm and 1000 pm. Microspheres may refer to lyophilized particles including reagents and / or active ingredients. In certain implementations, microspheres may include a polymer shell, such as one or more biodegradable polymers and / or water-soluble polymers, and optionally an inner core inside the shell. Microspheres in accordance with the present disclosure include those prepared by conventional techniques, which are known to those skilled in the art. For example, microspheres may be prepared by freezing a liquid into frozen pellets, followed by placing frozen microspheres in a dryer, such as a rotational dryer.
[0248] Lyophilized reagent beads or “lyo beads” (also known as “cryo pellets”) are generally spherical particles of lyophilized material ty pically having a diameter larger than 1,000 pm (or 1 millimeter (mm)). F or example, a lyo bead may have a diameter of about 1.8 mm, 2 mm, 4 mm, or 6 mm, or any diameter in between. As used herein, “lyospheres” refer to either lyophilized microspheres or lyophilized reagent beads. Lyospheres are not necessarily spheres or spherical but instead may be generally spheroid or spheroidal particles (that is, roughly spherical, or round while also being irregular or “lumpy”).
[0249] As used herein, the terms “coating” and “shell” include a composition that surrounds a core. In some implementations, a shell includes an outer layer of a microsphere. As used herein, the terms “core” and “core region” include any material within the surrounding shell. In various implementations, a core includes one or more lyophilized lyospheres. As used herein, the term “encapsulated microsphere” refers to microspheres that include a shell.
[0250] As used herein, the term “reagent” describes a single agent or a mixture of two or more agents useful for reacting with, interacting with, diluting, or adding to a sample and may include agents used in nucleic acid reactions, such as buffers, chemicals, enzymes, polymerase, primers including those having a size of less than 50 base pairs, template nucleic acids, nucleotides, labels, dyes, or nucleases. A reagent as described herein may, in certain implementations, include enzymes such as polymerases, ligases, recombinases, or transposases; binding partners such as antibodies, epitopes, streptavidin, avidin, biotin, lectins, or carbohydrates; or other biochemically-active molecules. Other example reagents include reagents for a biochemical protocol, such as a nucleic acid amplification protocol, an affinity-based assay protocol, an enzymatic assay protocol, a sequencing protocol, and / or a protocol for analyses of biological fluids. According to some implementations disclosed herein, a reagent may include one or more beads, such as magnetic beads, depending on specific workflows and / or downstream applications.
[0251] As used herein, “room temperature” refers to temperatures at or between 15 to 30° C, or at or between 17 to 23° C, or at or between 20 to 25° C.
[0252] The present disclosure relates to consumables containing one or more particles, including without limitation a core coating composite of materials having (i) an inner core optionally including releasable lyospheres of one or more workflow reagents; and optionally (ii) an outer coating encapsulating the inner core. The core coating composite material may be a macrosized, a micro-sized, or a nano-sized particle. In some implementations, the core includes, but is not limited to, one or more reagents, such as at least one enzyme, salt, surfactant, buffering agent, enzyme inhibitor, primer, nucleotide, magnetic bead, molecular probe, crowding agent, small molecule, labelled-nucleotide, a fluorophore, or any combination thereof.
[0253] In some implementations, the core coating composite may exhibit a total thickness of the coating structure of around 1-25 pm. As particular examples, the thickness may be selected from 2.5, 5. 10, 15, 20, or 25 pm. or the thickness may be provided in a range having an upper and lower limit selected from these values. In various implementations, the coating is between about 1 pm to 25 pm, between about 1 pm to about 20 pm, between about 5 pm to about 20 pm, between about 3 pm to about 10 pm, or between about 4 pm to about 6 pm, such as about 1 pm, about 2 pm. about 3 pm, about 4 pm, about 5 pm, about 6 pm, about 7 pm, about 8 pm, about 9 pm, about10 pm, about 1 1 pm, about 12 pm, about 13 pm, about 14 pm, about 15 pm, about 16 pm, about 17 pm, about 18 pm, about 19 pm, about 20 pm, about 21 pm, about 22 pm, about 23 pm, about 24 pm, or about 25 pm in thickness. The thickness may be advantageously adjusted.
[0254] In some implementations, the core coating composite material may be substantially spherical in shape with a diameter of about 0.2 pm to about 1,000 pm. As particular examples, the core coating composite material may have an average diameter of about 200 pm, 300 pm, 400 pm, 500 pm, 600 pm, 700 pm, 800 pm, 900 pm, or 1000 pm. In various implementations, the microspheres, with or without coating material, have a diameter from about 300 to 700 pm, from about 350 to 625 pm, or from about 400 to 600 pm. The core coating composite material may include substantially monodisperse particles, each having substantially the same average diameter. The core coating material may also include lyophilized microspheres or lyophilized beads having a distribution of average diameters. In some implementations, the core coating composite material may include a coating material selected from the group consisting of polyethylene glycol, betaine, and a salt.
[0255] The amount of coating material includes, for example, any amount suitable to produce a desired performance. In some implementations, the coating material is present in an amount between about 1 percent by weight (wt%) and about 100 wt% of the coating. For example, the coating material may be present in about 1 wt%, 2 wt%, 3 wt%, 4 wt%, 5 wt%, 6 wt%, 7 wt%, 8 wt%, 9 wt%, 10 wt%, 15 wt%, 20 wt%, 25 wt%, 30 wt%, 35 wt%, 40 wt%, 45 wt%, 50 wt%, 60 wt%, 70 wt%, 80 wt%, 90 wt%, or 100 wt% of the shell or any amount therebetween. In some implementations, the shell material is present in an amount between about 10 wt% and about 90 wt%, between about 10 wt% and about 80 wt%, between about 10 wt% and about 70 wt%. between about 10 wt% and about 6025 wt%, or between about 10 wt% and about 50 wt% of the shell.
[0256] The coating component as described herein may, in various implementations, include an additive. The coating additive may be present in an amount between about 0.01% weight by weight (w / w) of the coating and about 99% w / w of the coating. In some implementations, the coating additive is present in an amount between about 10% w / w and about 90% w / w of the coating. In some implementations, the coating additive is present in an amount between about 10% w / w and about 40% w / w. In some implementations, the coating additive is a moisture barrier material present in an amount no more than 90% w / w of the coating. In some implementations, the coating additive is present in an amount of at least 10% w / w concentration of the coating. For example, the coating additive may, in some implementations, be present in an amount between 0.1% w / w of the coating and about 15.0% w / w of the coating. As particular examples, the coating additive may be present in an amount of about 0.01% w / w, 0.05% w / w, 0.1% w / w, 0.5% w / w,1.0% w / w, 1.5% w / w, 2.0% w / w, 2.5% w / w, 3.0% w / w, 3.5% w / w, 4.0% w / w, 4.5% w / w, 5.0% w / w, 5.5% w / w, 6.0% w / w, 6.5% w / w, 7.0% w / w, 7.5% w / w, 8.0% w / w, 8.5% w / w, 9.0% w / w, 9.5% w / w, 10.0% w / w, 10.5% w / w, 11.0% w / w, 11.5% w / w, 12.0% w / w, 12.5% w / w, 13.0% w / w, 13.5% w / w, 14.0% w / w, 14.5% w / w, 15% w / w. or any amount therebetween. The amount of the coating additive may be adjusted to accommodate a particular reagent or combination of reagents or to accommodate a particular lyosphere composition.
[0257] Example coating additives include, but are not limited to, one or more of a polymer, a copolymer, a block copolymer, an anti-tacking agent (such as PEG stearates or Mg stearates, both mentioned below), an anti-static agent, an anti-foaming agent, a plasticizer, a polyvinyl alcohol (PVA), an ammonium salt, a conductivity promoter, a stearate derivative, an oleate derivative, a laurate derivative, a poly ether compound, an amino acid, tocopherol acetate, piperidyl sebacate, sodium salt, a buffer, a chelating agent, imidazolium salt, poly aniline, or any combination thereof. In some implementations, the polyether compound is selected from polyethylene glycol, polypropylene glycol, a block copolymer derived from ethylene oxide (EO) and propylene oxide (PO), or any combination thereof. In some implementations, the stearate derivative or oleate derivative is selected from magnesium stearate, PEG stearate, triglycerol stearate, sorbitan monostearate (SPAN 60), polysorbate 60 (TWEEN 60), glycerol trioleate, polysorbate 80 (TWEEN 80), or any combination thereof. In some implementations, the ammo acid is selected from one or more of leucine, isoleucine, phenylalanine, or any combination thereof. In some implementations, the polymer is neutral, cationic, or anionic. In some implementations, the sodium salt is selected from one or more of sodium chloride, sodium bisulfite, sodium citrate, or any combination thereof. In various implementations, the buffer is Trizma, tris hydrochloride (Tris-HC1 or “Tris”), bis-tris propane (BTP), 2-(N-cyclohexylamino)ethanesulfonic acid (CHES), 3-(N-morpholino)-propanesulfonic acid (MOPS), N-2-hydroxyethylpiperazine-N-2-ethane sulfonic acid (HEPES), or a combination thereof. In some implementations, the ammonium salt is selected from tetraalkyl ammonium chloride, tris(hydroxyethyl) alkylammonium chloride, or a combination thereof. In some implementations, the imidazolium salt is selected from l-ethyl-3-methyl-imidazolium salt or polyquatemium or LUVIQUAT (copolymer of vinyl pyrrolidone and quatemized vinylimidazole) or a combination thereof. In some implementations, the shell additive includes ammonium salt, copolymer, polyvinyl alcohol graft polyethylene glycol copolymer, polyvinyl alcohol (PVA), or any combination thereof. In various implementations, the shell additive is magnesium stearate or polyethylene glycol stearate.
[0258] As described herein, a “core” or “core region” includes any material within the encapsulating coating. A core in accordance with the present disclosure includes one or morelyophilized microspheres or lyophilized beads. The lyophilized microspheres or lyophilized beads of the present disclosure can include any reagent that is desired for controlled delivery and that can be unitized in substantially small sizes to be amenable to being lyophilized or particularized in size ranges described herein.
[0259] In some implementations, the inner core includes lyophilized reagents that are suitable for use in processing a biological sample using multiple sequential co-assays including lysis, DNA analysis, RNA analysis, protein analysis, metabolite analysis, tagmentation, nucleic acid amplification, nucleic acid sequencing, DNA library preparation, SBS technology, assay for transposase accessible chromatic using sequencing (ATAC-seq), contiguity-preserving transposition (CPT-seq), single cell combinatorial indexed sequencing (SCI-seq), single cell genome amplification, or any combination thereof performed sequentially. In some implementations, the composition is used for performing multiple co-assay reactions.
[0260] In accordance with this disclosure, arginine is deployed as a lyophilizationcompatible buffering agent to develop a DNA amplification mix for lyophilized format with enhanced stability of critical components across a range of pH values. Arginine is used in combination with other amino acids to thermally stabilize otherwise unstable proteins without perturbing protein-RNA interactions, both in liquid state and in lyophilized format. Such stabilization facilitates the use of non-thermostable polymerases at elevated temperatures. The approach generally involves a combination of three separate components to improve PCR performance: (i) a buffering agent (such as HEPES, ACES, PIPES, MOPSO, BES, MOPS, TES, TAPSO, POPSO, BICINE, TAPS, and AMPSO), (ii) an agent that improve the efficiency and / or accuracy of amplification, such as one giving at least +10% reaction yield (arginine or a polyamine like spermine or spermidine), and (iii) a version of the polymerase of interest, modified by protein engineering. Arginine can also be used in combination with the appropriate buffer to thermally stabilize triphosphate deoxy-nucleotides (triphosphates) and similar small molecules. As used herein, “efficiency” is the ability to generate good PCR yield with the minimum number of cycles possible (indicated as Ct or Cq in a qPCR test), while “accuracy” is the ability to copy, with high fidelity, DNA sequences that may be challenging to replicate.
[0261] Arginine also improves performance (such as efficiency or accuracy) of PCR reactions. The “elongation” phase of nucleic acid replication or transcription adds nucleotides one by one to a growing strand following a sequence dictated by a template strand. At least some elongation polymerases are determined to be a thermostable enzyme and to retain resistance to thermal denaturation when formulated in an arginine buffer. The arginine buffer also confers enhanced activity in a polymerase elongation assay. In combination with salt, PCR coadjutant, anddetergent, the arginine-based elongation polymerase formulation was tested in quantitative PCR (qPCR) reactions and delivered cycle threshold (Ct) values close to a target of 11 cycles ±1 cycle.
[0262] Therefore, the use of arginine as a buffering agent grants to one or more enzyme critical components both enhanced pH stability and improved performance. This effectively simplifies both the final formulation and the effort required to design and develop that formulation by removing the need for a screening campaign that identifies which stabilizer to include within the formulation. Similar benefits may also be achieved with respect to the stability of triphosphates. Unexpectedly, the formulation of arginine in combination with salt, PCR coadjutant, and detergent has the ability to maintain a consistent PCR performance (measured as Ct) across 0.9 pH units, a broad range desirable during the manufacturing stage because process specifications need not be set too narrowly and are therefore easy to apply, making the reagent robust for manufacturing purposes.
[0263] FIGS. 1 through 3 collectively illustrate an example screening process indicating that arginine suitably serves a pH buffer function in connection with lyophilized PCR reagents according to this disclosure. Arginine is zwitterionic, like many good buffers commonly used with enzymes, and therefore presents as a promising candidate.
[0264] FIG. 1 illustrates the pH range of various buffering systems compatible with lyophilized PCR enzymes. The pH ranges are indicated by a center value corresponding to pKa, the pH value at which the buffering systems offer the maximum buffering in accordance to the Henderson-Hasselbalch equation and calculated using the negative base-10 logarithm of the acid dissociation constant (Ka). A lower bound of each pH range indicated corresponds to pKa-0.5, while the upper bound corresponds to pKa+0.5. The buffering systems are identified by the primary buffering agent, which include glycine, ethanolamine, CHAPS, arginine, AMPD, Tris, HEPES, MOPS, citrate, and histidine.
[0265] FIG. 2 illustrates the differential scanning fluorimetry (DSF) response of an example formulation as a function of temperature in degrees Celsius (°C). Fluorescence is indicated for a ratio of 350 nanometers (nm) to 330 nanometers, plotted as a function of melting temperature Tm. The plot of FIG. 2 corresponds to use of a NANOTEMPER NT40 instrument to perform thermal screening. The regions are marked in which folded and unfolded proteins are expected, together with an expectation of possible thermal denaturation.
[0266] FIG. 3 illustrates enzyme activity screening for an example formulation. Relative fluorescence 301 as a function of time (in minutes) following magnesium ion (Mg2+) primed injection is depicted for an intercalating dye. The relative fluorescence range of 0.200 to 1.000 and an operating point of 0.600 are marked on the plot. The figure represents a re-adaptation of whatpublished by Montgomery, J.L. et al. in Analytical Biochemistry, vol. 441, issue 2 (2013), pp 133-139.
[0267] FIGS. 4A and 4B illustrate example characteristics of arginine as a function of pH according to this disclosure. More specifically, FIG. 4A illustrates elongation activity (vO / [E]) as a function of pH, with arginine data 401, 402 marked for pH 8.59 and 9.59, respectively. FIG. 4B illustrates melting temperature Tm (in degrees Celsius) as a function of pH, again with arginine data 411, 412 marked for pH 8.59 and 9.59, respectively. The amplification mixture exhibits good stability across a predetermined pH range, which may fall within about pH 8.59 to about pH 9.59 or, alternatively, is within that range up to about pH 9.2.
[0268] FIG. 5 illustrates PCR performance of an example formulation using an arginine buffer in cycle threshold (Ct) values as a function of pH according to this disclosure. The example formulation includes an arginine buffer in combination with salt, a PCR coadjutant, and a detergent. The amount of arginine buffer may be 20 to 180 millimolar (mM), preferably between 40-80mM. The example formulation may further include: 100 to 200mM salt (such as sodium chloride (NaCl) or potassium chloride (KC1)), preferably 20-40mM; 0 to 6 molar (M) of commercially available or other PCR coadjutant, preferably 0.045-0.228M and even more preferably between 0.112-0.19M; and 0 to 0.2 percent by volume (%V) detergent (such as Brij23, Tween20, Triton-XlOO, or CHAPS), preferably 0-0.1%V. In addition, a cofactor such as magnesium salt may be included at a concentration of l-40mM, preferably 5-8mM. The example formulation can maintain a consistent PCR performance 501 of the polymerase (~ 13 Ct at about pH 8.4) across 0.9 pH units and close to the ideal target 502 of 11±1 Ct. Unexpectedly, in the example formulations, arginine outperformed many common buffers in terms of retaining the target activity across the broadest possible range of pH, which is a very desirable property on the perspective of manufacturing.
[0269] FIG. 6 illustrates example glass transition temperature Tg' for various excipients in the presence of an arginine buffer according to this disclosure. The arginine-based formulation interacts with a variety of excipients (in this example, one excipient only, per formulation) to improve the freezing temperature of the reagent. The same reagent formulation was generated with either the standard Tris buffer (represented by the left fourteen bars 601 in FIG. 6), frequently used for molecular biology applications, or an arginine buffer as described above (represented by the right fourteen bars 602 in FIG. 6). When the arginine buffer formulation is combined with a variety of different excipients, grouped by chemical property in FIG. 6, the arginine buffer enables an increase of Tg’ for the mixture to a range of values systematically higher than those associated with the same excipients combined with the Tris buffer.
[0270] Since the value of Tg’ represents the temperature below which the product can be successfully frozen during lyophilization, a relatively high value of Tg’ leads to easier lyophilization by shortening the freezing time. The higher Tg’ and shorter freezing time, in turn, make the design and execution of the freeze-drying process both easier and cheaper (such as by requiring less energy). Here, the extent of the Tg’ increase can be determined according to the nature of the excipient, with the interaction between arginine and polyols / polysaccharide-based polymers being particularly effective. The various excipients may be classified as follows: stabilizers 603 (such as caffeine); bulking agents 604 (such as (2-hydroxypropyl)-alpha-cyclodextrin (HPACD), L-isoleucine, polyethylene glycol (PEG) 6K, and polyvinylpyrrolidone (PVP) 40); monosaccharides 605 (such as inositol, L-rhamnose); disaccharides 606 (such as trehalose, sucralose); trisaccharides 607 (such as D-(+)-Raffinose); mono- / di- / tri-saccharide derived polyols 608 (such as D-(-)-mannitol, meso-Erythritol, and D-sorbitol); and maltotriosederived polymer 609 (such as pullulan).
[0271] FIG. 7 illustrates example nucleotide stability of an arginine-based formulation according to this disclosure. The absorbance (in milli-absorbance units, mAU) of various formulations as measured as a function of retention time (minutes) is depicted. For each trace, the same reagent formulation was generated with the arginine buffer 701 described above or, for comparison, either the standard Tris buffer 702 frequently used for molecular biology applications or a CHES buffer 703. After a period of incubation in liquid format (pre-lyophilization), the various formulations were analyzed by high-performance liquid chromatography (HPLC). Four peaks, one per each of the natural dNTPs, are present. With respect to a reference solution of dNTPs in the Tris stock buffer, the arginine formulation displayed larger peak areas, while the formulation with the CHES buffer performed the worst of the three. This indicates that the arginine buffer helps to stabilize natural deoxynucleotides in solution.
[0272] The discussion above of FIGS. 1-7 relates to use of arginine-based formulations that can (but do not necessarily) include arginine as either the sole or primary’ lyophilizationcompatible pH buffering agent. As described, arginine boosts activity and lowers Ct. However, arginine alone can, in some implementations, result in relatively’ poor quality of the lyophilized product, such as inconsistent homogeneity’ within the final lyophilized product. Insufficient homogeneity can implicate reliability’ of the formulation upon rehydration.
[0273] FIG. 8 illustrates PCR performance of an example formulation using a CHES buffer in cycle threshold (Ct) values as a function of pH, analogous to FIG. 5, together with the molecular structure of CHES. With the only difference being the use of CHES as opposed to arginine, conditions are identical to those in FIG. 5, namely: the amount of CHES buffer may be about 20to about 180 mM, preferably between about 20 and about 80 mM or between about 40 and about 80 mM. The example formulation may further include: 100 to 200 mM salt (such as sodium chloride (NaCl) and / or potassium chloride (KC1)), preferably about 20 to about 40 mM; 0 to about 6 M of a commercially available or other PCR coadjutant (an alkyl-substituted quaternary ammonium salt), preferably about 0.045 to about 0.228 M and even more preferably between about 0.112 to about 0.19 M; and 0 to 0.2 %V detergent (such as Brij23, Tween20, Triton-XlOO, or CHAPS), preferably 0 to about 0.1 %V. In addition, a cofactor such as magnesium salt (e.g., magnesium chloride) may be included at a concentration of about 1 to about 40 mM, preferably about 5 to about 8 mM. As illustrated in FIG. 8, the example CHES-based liquid formulation displays consistent PCR performance 801 over 0.5 units of pH (again relative to the ideal target 802 of 11±1 Ct), according to data modelling produced by a series of design of experiments (DoE) studies. The right-most vertical dotted line 803 in FIG. 8 represents where the solution loses too much performance according to the DoE results (with an acceptable range for success set between 11-15 Ct).
[0274] FIGS. 9A-9C illustrate example glass transition temperature Tg' for various excipients in the presence of different buffers, analogous to FIG. 6. Once again, the same reagent formulation was generated (in this example, with one excipient only) for each buffer: tris (represented by bars 901 in FIG. 9A); arginine (represented by bars 902 in FIG. 9A); CHES (represented by bars 903 in FIG. 9B); N-(l,l-Dimethyl-2 -hydroxy ethyl)-3-amino-2-hydroxypropanesulfonic acid (AMPSO) (represented by bars 904 in FIG. 9B); N,N-bis(2-hydroxyethyljglycine (bicine) (represented by bars 905 in FIG. 9C); and glycine (represented by bars 906 in FIG. 9C). As apparent from FIGS. 9A-9C. the arginine and CHES buffers have generally similar glass transition temperatures Tg' with the different excipients. In FIGS. 9A-9C, differential scanning fluorimetry (DSF) of the CHES-based crude formulations 903 is compared with the same crude formulations generated using five different buffer backgrounds 901, 902, 904, 905, and 906. CHES is generally associated with Tg’ values greater than -30 °C. a generally favorable figure for lyophilization processes because a more efficient primary drying step of the lyophilization cycle is enabled. With the exception of arginine, none of the other buffers tested displayed the same tendency to promote high Tg' values.
[0275] FIG. 10 illustrates median glass transition temperature Tg' (with ranges indicated) for the different buffers of FIG. 9. Median rather than mean glass transition temperatures are considered, due to the crude formulations including different excipients. The crude formulations displayed a generally high value of Tg’ when formulated in CHES. The median Tg' values across all of the excipients demonstrates that CHES-based crude formulations are characterized by thehighest Tg' values, followed by the arginine-based formulations. This property (highest Tg' values) is believed to be directly related to the tendency of CHES to generate “elegant” cakes as discussed below upon freeze-drying, even in the absence of any excipient molecule.
[0276] FIG. 11 illustrates robustness of arginine- and CHES-based crude formulations to freeze / thaw stress. Mean Cq is plotted for different excipients, with the arginine-based crude formulations segregated from the CHES-based crude formulations since, as shown in the righthand Y axis, those formulations are lyophilized at 7% weight by volume (w / V) rather than at the 5% w / V for the CHES-based crude formulations. The arginine and CHES-based formulations include a formulation 1001 of arginine and lactobionate and a formulation 1002 of arginine and succinate. The CHES-based formulations include a formulation 1003 of CHES and rhamnose, a formulation 1004 of CHES and sucralose, a formulation 1005 of CHES and raffinose, a formulation 1006 of CHES and mannitol, a formulation 1007 of CHES and erythritol, a formulation 1008 of CHES and lactitol, and a formulation 1009 of CHES and sorbitol. Each series plots Cq according to the number of freeze / thaw cycles: 0 for the left-most column, 3 for the center column, and 6 for the right-most column. When tested by qPCR and compared w ith a target value of Cq = 11±1, a subset of the CHES-based crude formulations displayed relatively little loss of polymerase performance, and produced elegant cakes on being subjected to freeze-drying.
[0277] TABLE 1 below tabulates the composition of the excipient library used to derive the data used for FIGS. 9 through 11. The excipients are classified by role. The three right-hand columns relate the excipient concentration for lyophilization, which correspond to a 5X of the final concentration in the qPCR reaction.Excipient# Component Category / Role High% Medium % Low % 1 arginine: lactobionate bulk stabilizing 325:25mM 325:50mM 325:75mM excipient forarginine buffer2 arginine (ph 9): bulk stabilizing 325:25mM 325:50mM 325:75mM succinate excipient forarginine buffer3 L-isoleucine primary bulking 3.8 2 1agent4 L-Leucine primary bulking 2 1 0.5agentExcipient# Component Category / Role High% Medium % Low % 5 PEG 6K primary bulking 20 10 5 agent6 PVP-40 primary bulking 20 10 5 agent7 caffeine stabilizer / 2.3 1 0.1 complexing agent8 HPACD stabilizer / 20 10 5 complexing agent9 HPBCD stabilizer / 20 10 5 complexing agent0 inositol monosaccharide 20 10 5 1 L-rhamnose monosaccharide 12 10 5 2 maltose disaccharide, 20 10 5 reducing3 sucralose disaccharide, non20 10 5 reducing4 sucrose disaccharide, non20 10 5 reducing5 D-(+)-melezitose trisaccharide, non20 10 5 reducing6 D-(+)-raffinose trisaccharide 20 10 5 pentahydrate7 trehalose trisaccharide 20 10 5 8 Pullulan polymer 14.3 10 5 9 D-(-)-mannitol monosaccharide12 10 5 derived polyol aslyoprotectant0 meso-erythritol monosaccharide20 10 5 derived polyol aslyoprotectantExcipient# Component Category / Role High% Medium % Low % 21 Xylitol monosaccharide20 10 5derived polyol aslyoprotectant22 isomalt disaccharide20 10 5derived polyol23 lactitol disaccharide20 10 5derived polyol24 D-sorbitol disaccharide20 10 5derived polyol25 Betaine (+ TMAC) PCR coadjutant 5 3 1.5 26 Betaine (- TMAC) PCR coadjutant 5 3 1.5 27 maltotriose trisaccharide 20 10 5TABLE 1
[0278] FIGS. 12A and 12B illustrate key properties of CHES-based liquid formulations, relative to lyophilization in cake form. The CHES-based liquid formulation described above in connection with FIG. 8 is lyophilized. FIG. 12A depicts a CHES-based formulation 1201 without any excipients that, after freeze-drying, forms elegant cakes 1202; FIG. 12B depicts the CHES-based formulation 1211 with one excipient of a library 1213 of excipients that, after freeze-drying, forms elegant cakes 1212. '‘Elegant” cakes are those having a homogenous appearance and exhibiting mechanical integrity (i.e., not collapsed, since a collapsed cake suggests that the formulation is unlikely to produce a homogenous mixture upon rehydration and may implicate accelerated aging of the formulation). FIGS. 9, 10, 11, and 12A-12B illustrate benefits of using a CHES-based buffer when lyophilizing protein-based reagents while also simplifying reagent development.
[0279] FIG. 13 illustrates titration of arginine in CHES-based formulations according to the present disclosure. While arginine boosts PCR performance, addition of CHES improves lyophilized product formation, with the combination of arginine and CHES expected to provide benefits in both PCR performance and lyophilized product formation. For the images in FIG. 13, the same PCR master mix described in connection with FIG. 8 was formulated with two different total buffer concentrations: 100 mM (top panel) and 200 mM (bottom panel). Arginine was titrated in CHES, from 0% arginine + 100% CHES (left) to 100% arginine + 0% CHES (right). As previously discussed, formulations using 200 mM CHES tend to form elegant cakes upon freeze-drying. For the 200 mM total buffer concentration used for FIG. 13, the appearance of the cakes for the combination of arginine and CHES is reasonably elegant up to 10% arginine.
[0280] In various implementations of the arginine and CHES-based buffer, the amount of arginine is between about 0 mM and about 200 mM and the amount of CHES is between about 0 mM and 200 mM. In some implementations of the arginine and CHES-based buffer, the amount of arginine is between about 10 mM and about 80 mM and the amount of CHES is between about 0 mM and 200 mM. In some implementations of the arginine and CHES-based buffer, the amount of arginine is between about 0 mM and about 200 mM and the amount of CHES is between about 10 mM and 80 mM. It will be understood that selection of amounts from those ranges is based on combined amounts of arginine and CHES producing a total buffer system concentration within the overall formulation of (for example) about 100 mM or about 200 mM, as depicted in FIG. 13.
[0281] FIG. 14 illustrates PCR performance, expressed as Ct value, for the PCR master mixtures of FIG. 13. Trace 1401 corresponds to the 100 mM total buffer concentration images in FIG. 13, while trace 1402 corresponds to the 200 mM total buffer concentration images. As shown, the combination of 200 mM total buffer concentration with 10-30% arginine added to a CHES buffer yields notable improvement in PCR performance.
[0282] FIGS. 8 through 14 relate to cake-form lyophilized materials. A cake form is used to illustrate benefits of an arginine-based, CHES-based, or arginine and CHES-based buffer systems for lyophilizing protein-based reagents with simplified reagent formulations. Similar benefits of using such buffers systems are believed to result for microspheres, avoiding issues that are analogous to non-elegant or collapsed cakes (e.g., particles that are non-homogenous or not spherical, etc.).
[0283] FIGS. 15A through 15D and 16 illustrate that microspheres can be successfully generated with a formulation including a CHES-based buffer. FIGS. 15 A through 15D are images of microspheres generated with a CHES-based buffer formulation. FIGS. 15A and 15B are microscopic images, while FIGS. 15C and 15D are scanning electron microscope (SEM) images with higher magnifications and / or resolutions than those in FIGS. 15A-15B.
[0284] FIG. 16 is a plot of the size and distribution of microspheres generated with a formulation containing CHES. The median size is 503.55 pm, the mean size is 503.86 pm, the standard deviation is 21.78 pm, and the span (range) is 0.047. Physical properties of the microspheres are tabulated in TABLE 2 below:Tg’ (°C) -38.25Tc (°C) -33 Glass transition temperature (Tg) @ 0% relative humidity (RH) (°C) 72.67Tg @ 20% RH (after 24 hours) (°C) 40.25 Dynamic vapor sorption (DVS) 30TABLE 2
[0285] In addition, the presence of CHES contributes to stabilization of small molecules (e.g., deoxynucleotides) within microspheres. Linear, sequential library preparation workflows are affected by all upstream changes, including buffer system, concentration, and pH. However, of all lyophilized material stabilization approaches studied, buffer systems offered the largest stabilizing effect. Among common buffers, CHES and HEPES are the best performers. FIG. 17 illustrates the how much of the original amount of adenosine triphosphate (ATP) is successfully preserved (%ATP) during storage for cakes stressed at 40°C for three weeks. Tris at pH 8 (range: pH 7-9) and 130 mM is used as a control, with CHES tested at a buffer pH range of 8.6-10 and concentrations from 70-160 mM, and HEPES tested at a buffer pH range of 6.8-8.2 and concentrations also from 70-160 mM. For both CHES and HEPES, pH had no observable effect on stability and lower concentrations (e.g., 70 mM) resulted in better stability.
[0286] An A-tailing mixture ATI including a CHES-based buffer is determined to improve small molecule stability significantly. TABLE 3 tabulates anticipated risk levels for small molecules associated with modifying an existing A-tailing mixture AT0 to include new CHES-based buffers (in mixture ATI):A-Tailing Risk Level (small molecules)Version Lyo Stability Performance AT0 Low Med LowATI (new buffers) Low Low LowTABLE 3
[0287] FIG. 18 illustrates that formulations using ATI are well lyophilized, producing elegant cakes. FIG. 19 illustrates that the CHES-based A-Tailing mixture ATI results in slower small molecule degradation (based on %ATP) when stored at 50°C for 3 weeks that HEPES or Tris. FIGS. 20A and 20B illustrate that the new CHES-based buffer in the A-Tailing mixture ATI has negligible impact on functional workflow and shows comparable performance to a control.
[0288] Although this disclosure has been described with reference to various example implementations, various changes and modifications may be suggested to one skilled in the art. Itis intended that this disclosure encompass such changes and modifications as fall within the scope of the appended claims.
Claims
WHAT IS CLAIMED IS:
1. A composition for processing a biological sample, the composition comprising: lyophilized material including:an amplification mixture for amplifying one of nucleic acids or deoxynucleotide triphosphates (dNTPs); anda pH buffer system comprising arginine in an amount sufficient to increase stability of the amplification mixture across a predetermined pH range.
2. The composition of claim 1, wherein the amount of the arginine is between 20 and 180 millimolar (mM).
3. The composition of claim 2, wherein the amount of the arginine is between 40 and 80 mM.
4. The composition of claim 1, wherein the predetermined pH range is up to and includes 0.9 pH units.
5. The composition of claim 1, wherein the predetermined pH range falls within pH 8.59 to pH 9.2.
6. The composition of claim 1, wherein the arginine further increases glass transition temperature of the lyophilized material.
7. The composition of claim 1, wherein the arginine further increases stability of one or more nucleotides present within the amplification mixture.
8. The composition of claim 1, wherein the amplification mixture comprises an elongation polymerase.
9. The composition of claim 1, wherein the amplification mixture comprises an elongation polymerase, the composition further comprising:100 to 200 millimolar (mM) salt;0 to 6 molar (M) of a polymerase chain reaction (PCR) coadjutant; and0 to 0.2 percent by volume (%V) detergent.
10. The composition of claim 9, wherein the composition comprises 20 to 40 mM of the salt.
11. The composition of claim 9, wherein the composition comprises 0.112 to 0.19 mM of the PCR coadjutant.
12. The composition of claim 9, wherein the composition maintains consistent PCR performance for a cycle threshold (Ct) value of approximately 13 across 0.9 pH units.
13. The composition of claim 9, wherein the composition comprises 5 to 8 mM of a magnesium salt.
14. A method of formulating a consumable for processing a biological sample, the method comprising:selecting a buffer system comprising a selected amount of arginine;adding the buffer system to an amplification mixture for amplifying one of nucleic acids or deoxynucleotide triphosphates (dNTPs), wherein the selected amount of arginine is sufficient to increase stability of the amplification mixture across a predetermined pH range; and lyophilizing a composition including the amplification mixture and the buffer system to form a lyophilized material.
15. The method of claim 14, wherein the selected amount of the arginine is between 20 and 80 mM.
16. The method of claim 14, wherein at least a portion of the predetermined pH range falls within pH 8.59 to pH 9.59.
17. The method of claim 14, wherein the amplification mixture comprises an elongation polymerase, the composition further comprising:100 to 200 millimolar (mM) salt;0.045 to 0.19 mM of a polymerase chain reaction (PCR) coadjutant; and0 to 0.2 percent by volume (%V) detergent.
18. A method comprising:lyophilizing a composition including an amplification mixture for amplifying one of nucleic acids or deoxynucleotide triphosphates (dNTPs). and a buffer system to form a lyophilized material, wherein the buffer system comprises an amount of arginine sufficient to increase stability of the amplification mixture across a predetermined pH range.
19. The method of claim 18, wherein the amount of the arginine is between 20 and 80 mM.
20. The method of claim 18, wherein the predetermined pH range is up to and includes 0.9 pH units.
21. The method of claim 18, wherein the predetermined pH range falls within pH 8.59 to pH 9.2.
22. The method of claim 18, wherein the amplification mixture comprises an elongation polymerase.
23. The method of claim 18, wherein the amplification mixture comprises an elongation polymerase, the composition further comprising:100 to 200 millimolar (mM) salt;0.045 to 0.19 mM of a polymerase chain reaction (PCR) coadjutant; and0 to 0.2 percent by volume (%V) detergent.
24. The method of claim 23, wherein the composition comprises 0.045 to 0.228 mM of the PCR coadjutant.
25. The method of claim 23, wherein the composition maintains consistent polymerase chain reaction (PCR) performance for a cycle threshold (Ct) value of approximately 13 across 0.9 pH units.
26. The method of claim 18, wherein the composition comprises 5 to 8 mM of a magnesium salt.
27. A method, comprising:selecting a buffer system comprising a selected amount of arginine and a selected amount of 2-(N-cyclohexylamino)ethanesulfonic acid (CHES);adding the buffer system to an amplification mixture for amplifying one of nucleic acids or deoxynucleotides, wherein the selected amount of arginine and the selected amount of CHES are sufficient to increase stability of the amplification mixture across a predetermined pH range; andlyophilizing a composition including the amplification mixture and the buffer system to form a lyophilized material that is consumable during processing of a biological sample.
28. The method of claim 27, wherein the selected amount of the arginine is between about 10 to about 80 mM and the selected amount of CHES is between 0 and about 200 mM.
29. The method of claim 27, wherein the selected amount of the arginine is between 0 to about 200 mM and the selected amount of CHES is between 10 and about 80 mM.
30. The method of claim 27, wherein the selected amount of the arginine is 0 mM and the selected amount of CHES is between about 20 and about 180 mM.
31. The method of claim 27, wherein the selected amount of CHES is between about 40 and about 80 mM.
32. The method of claim 27, wherein the predetermined pH range is at least 0.5 pH units.
33. The method of claim 27, wherein at least a portion of the predetermined pH range falls within pH 8.59 to pH 9.59.
34. The method of claim 27, wherein the buffer system further increases glass transition temperature of the lyophilized material.
35. The method of claim 27, wherein the amplification mixture comprises an elongation polymerase.
36. The method of claim 35, wherein the elongation polymerase is thermostable and retains resistance to thermal denaturation based on presence of the arginine.
37. The method of claim 27, wherein the lyophilized material produces a substantially homogenous mixture when rehydrated.
38. The method of claim 27, wherein the lyophilized material comprises a cake.
39. A method, comprising:providing a receptacle containing a lyophilized material that is consumable during processing of a biological sample, the lyophilized material comprising a buffer system and an amplification mixture for amplifying one of nucleic acids or deoxynucleotide triphosphates (dNTPs), the buffer system comprising a selected amount of arginine and a selected amount of 2-(N-cyclohexylamino)ethanesulfonic acid (CHES), wherein the selected amount of arginine and the selected amount of CHES are sufficient to increase stability’ of the amplification mixture across a predetermined pH range; andrehydrating the lyophilized material to form a liquid reagent mixture for a sequencing process in the receptacle.
40. The method of claim 39, further comprising:adding a portion of the liquid reagent mixture from the receptacle to a test site for a biological sample.
41. The method of claim 39, wherein the selected amount of the arginine is between about 10 to about 80 mM and the selected amount of CHES is between 0 and about 200 mM.
42. The method of claim 39, wherein the selected amount of the arginine is between 0 to about 200 millimolar (mM) and the selected amount of CHES is between 10 and about 80 millimolar (mM).
43. The method of claim 39, wherein the selected amount of the arginine is 0 millimolar (mM) and the selected amount of CHES is between about 20 and about 180 millimolar (mM).
44. The method of claim 39, wherein the selected amount of CHES is between about 40 and about 80 millimolar (mM).
45. The method of claim 39. wherein the predetermined pH range is at least 0.5 pH units.
46. The method of claim 39, further comprising:mixing the liquid reagent mixture with an analyte.
47. The method of claim 46, wherein the analyte comprises one or more nucleic acid samples.
48. The method of claim 46, further comprising:determining a nucleotide of a sequence for the analyte.
49. The method of claim 46, further comprising:cleaving a chemical blocker from the analyte.
50. The method of claim 39, further comprising:flowing the liquid reagent mixture through a flow cell having a plurality' of reaction sites.
51. The method of claim 50, wherein the plurality of reaction sites comprises strands of one or more nucleotides that each comprise a clonal cluster of strands of different nucleotides among the one or more nucleotides at different reaction sites among the plurality7of reaction sites.
52. The method of claim 50, wherein each of the plurality of reaction sites comprises a clonal cluster of strands of nucleotides.
53. A consumable product, comprising:a receptacle; anda lyophilized material within the receptacle that is consumable during processing of a biological sample, the lyophilized material comprisingan amplification mixture for amplifying one of nucleic acids or deoxynucleotide triphosphates (dNTPs), anda buffer system comprising a selected amount of arginine and a selected amount of 2-(N-cyclohexylamino)ethanesulfonic acid (CHES), wherein the selected amount of arginine and the selected amount of CHES are sufficient to increase stability of the amplification mixture across a predetermined pH range,wherein rehydration of the lyophilized material forms a liquid reagent mixture for a sequencing process in the receptacle.
54. The consumable product of claim 53, wherein the selected amount of the arginine is between about 10 to about 80 millimolar (mM) and the selected amount of CHES is between 0 and about 200 millimolar (mM).
55. The consumable product of claim 53, wherein the selected amount of the arginine is between 0 to about 200 millimolar (mM) and the selected amount of CHES is between 10 and about 80 millimolar (mM).
56. The consumable product of claim 55, wherein the selected amount of CHES is between about 40 and about 80 millimolar (mM).
57. The consumable product of claim 53, wherein the buffer system further increases stability of one or more nucleotides present within the amplification mixture.
58. The consumable product of claim 53, wherein the buffer system further thermally stabilizes one or more enzymes within the amplification mixture.
59. The consumable product of claim 53, wherein the amplification mixture comprises an elongation polymerase.
60. A composition, comprising:a lyophilized material for processing a biological sample, the lyophilized material comprising:an amplification mixture for amplifying one of nucleic acids or deoxynucleotide triphosphates (dNTPs), anda buffer system comprising a selected amount of arginine and a selected amount of 2-(N-cyclohexylamino)ethanesulfonic acid (CHES), wherein the selected amount ofarginine and the selected amount of CHES are sufficient to increase stability of the amplification mixture across a predetermined pH range.
61. The composition of claim 60, wherein the selected amount of the arginine is 0 millimolar (mM) and the selected amount of CHES is between about 20 and about 180 millimolar (mM).
62. The composition of claim 60, wherein the selected amount of CHES is between about 40 and about 80 millimolar (mM).
63. The composition of claim 60, wherein the predetermined pH range is at least 0.5 pH units.
64. The composition of claim 60, wherein the amplification mixture comprises an elongation polymerase that is thermostable and retains resistance to thermal denaturation based on presence of the arginine.
65. A method, comprising:providing a receptacle containing a lyophilized material that is consumable during processing of a biological sample, the lyophilized material comprising a buffer system and an amplification mixture for amplifying one of nucleic acids or deoxynucleotide triphosphates (dNTPs). the buffer system comprising a selected amount of 2-(N-cyclohexylamino)ethanesulfonic acid (CHES), wherein the selected amount of CHES is sufficient to increase stability' of the amplification mixture across a predetermined pH range; and rehydrating the lyophilized material to form a liquid reagent mixture for a sequencing process in the receptacle.
66. The method of claim 65, further comprising:adding a portion of the liquid reagent mixture from the receptacle to a test site for a biological sample.
67. The method of claim 65, wherein the selected amount of CHES is between 10 and about 80 millimolar (mM).
68. The method of claim 67, wherein the selected amount of CHES is between about 40 and about 80 mM.
69. The method of claim 67. wherein the predetermined pH range is at least 0.5 pH units.
70. The method of claim 67, wherein the amplification mixture comprises an elongation polymerase.
71. The method of claim 67, wherein the lyophilized material comprises a cake.
72. The method of claim 67, further comprising:mixing the liquid reagent mixture with an analyte, wherein the analyte comprises one or more nucleic acid samples.
73. The method of claim 72, further comprising:determining a nucleotide of a sequence for the analyte.
74. The method of claim 72, further comprising:cleaving a chemical blocker from the analyte.
75. The method of claim 67, further comprising:flowing the liquid reagent mixture through a flow cell having a plurality of reaction sites.
76. The method of claim 75, wherein the plurality of reaction sites comprises strands of one or more nucleotides, and wherein the strands of one or more nucleotides comprise a clonal cluster of strands of different nucleotides among the one or more nucleotides at different reaction sites among the plurality of reaction sites.
